Ovarian cancer

Back to Top
Are you looking for a regimen but can't find it here? It is possible that we've moved it to the historical regimens page. For placebo or observational studies in this condition, please visit this page. If you still can't find it, please let us know so we can add it!.
Note: The majority of regimens on this page were designed for the most common histology of ovarian cancer - high-grade serous ovarian cancer (HGSOC). 
The following links will take you to biomarker-specific subpages: 
*Regimens for HRD-positive ovarian cancer are here.
The following links will take you to histology-specific subpages:
*Regimens for low-grade serous ovarian cancer (LGSOC) are here.
Last updated on 2024-12-02:52 regimens on this page
98 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==ASCO==
*2025: Gaillard et al. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update EuroPMC
**2016: Wright et al. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline EuroPMC
*2022: Tew et al. Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update EuroPMC
**2020: Tew et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline link to PMC article EuroPMC
*2021: Vanderpuye et al. Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline link to PMC article EuroPMC
*2020: Konstantinopoulos et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline link to PMC article EuroPMC
==ESMO==
*2023: González-Martín et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up EuroPMC
**2013: Ledermann et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up EuroPMC
**2010: Colombo et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up EuroPMC
**2009: Aebi & Castiglione. Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up EuroPMC
**2008: Aebi & Castiglione. Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up EuroPMC
**2007: Vasey. Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up EuroPMC
**2005: Vasey et al. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of epithelial ovarian carcinoma EuroPMC
*2018: Ray-Coquard et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up EuroPMC
**2012: Colombo et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up EuroPMC
**2009: Colombo et al. Non-epithelial ovarian cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up EuroPMC
==ESMO/ESGO/ESP==
*2024: Ledermann et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease EuroPMC
**2019: Colombo et al. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease EuroPMC
==NCCN==
*NCCN Guidelines - Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer
**2021: Armstrong et al. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. EuroPMC
**2016: Morgan et al. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology EuroPMC
**2013: Morgan et al. Ovarian cancer, version 2.2013. EuroPMC
**2012: Morgan et al. Ovarian cancer, version 3.2012. EuroPMC
**2011: Morgan et al. Epithelial ovarian cancer. EuroPMC
**2008: Morgan et al. Ovarian cancer. Clinical practice guidelines in oncology. EuroPMC
**2006: Morgan et al. Ovarian cancer. Clinical practice guidelines in oncology. EuroPMC
**2004: Morgan et al. Ovarian cancer clinical practice guidelines. EuroPMC
*NCCN Guidelines - Genetic/Familial High-Risk Assessment: Breast and Ovarian
==SGO/ASCO==
*2016: Wright et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline EuroPMC
=Adjuvant therapy for early stage disease=
==Carboplatin monotherapy==
===Regimen variant #1, AUC 5===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Colombo et al. 2003 (ICON1)	1991-2000 	Phase 3 (E-esc)	Observation	Longer OS1 (primary endpoint)OS60: 82% vs 74%(HR 0.67, 95% CI 0.50-0.90)
1Reported efficacy is based on the 2003 pooled update.
Note: this was one of the recommended regimens for the experimental arm; other regimens were also used (see original paper).
====Preceding treatment====
*Surgery
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 5 IV once on day 1
21-day cycle for 6 cycles
===Regimen variant #2, 350 mg/m2===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Trimbos et al. 2003 (ACTION)	1990-2000 	Phase 3 (E-esc)	Observation	Longer OS1 (primary endpoint)OS60: 82% vs 74%(HR 0.67, 95% CI 0.50-0.90)
1Reported efficacy is based on the 2003 pooled update.
Note: this was one of the recommended regimens for the experimental arm; other regimens were also used (see original paper). Cycle length was not specified in the paper; 21-day cycle is typical for this drug.
====Preceding treatment====
*Surgery
====Chemotherapy====
*Carboplatin (Paraplatin) 350 mg/m2 IV once on day 1
21-day cycle for 4 to 6 cycles (see note)
===References===
# ACTION: Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S; EORTC-ACTION collaborators. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003 Jan 15;95(2):113-25. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
## Pooled update: Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, Lissoni A, Swart AM; International Collaborative Ovarian Neoplasm 1; EORTC Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003 Jan 15;95(2):105-12. link to original article EuroPMC
# ICON1: Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, Torri V, Williams C, Lissoni A, Bonazzi C; ICON. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst. 2003 Jan 15;95(2):125-32. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00002477
## Pooled update: Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, Lissoni A, Swart AM; International Collaborative Ovarian Neoplasm 1; EORTC Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003 Jan 15;95(2):105-12. link to original article EuroPMC
==Carboplatin & Paclitaxel (CP)==
CP: Carboplatin & Paclitaxel
===Regimen variant #1, 6/175===
Study 	Dates of enrollment	Evidence
Mannel et al. 2011 (GOG-0175)	1998-2006 	Non-randomized part of phase 3 RCT
====Preceding treatment====
*Surgery
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 6 IV once on day 1
*Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
21-day cycle for 3 cycles
====Subsequent treatment====
*Observation versus Paclitaxel maintenance
===Regimen variant #2, 7.5/175===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Bell et al. 2006 (GOG 157)	1995-1998 	Phase 3 (C)	CP x 6 	Did not meet primary endpoint of RR
====Preceding treatment====
*Surgery
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 7.5 IV over 30 minutes once on day 1
*Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
21-day cycle for 3 cycles
===References===
# GOG 157: Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, Rose GS, Spirtos NM; Gynecologic Oncology Group. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Sep;102(3):432-9. Epub 2006 Jul 24. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# GOG-0175: Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, Degeest K, Cohn DE, Monk BJ, Michael H. A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Jul;122(1):89-94. Epub 2011 May 6. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00003644
=Neoadjuvant chemotherapy for advanced stage disease=
==Carboplatin & Paclitaxel (CP)==
===Regimen variant #1, AUC 5/175 x 3===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Kehoe et al. 2015 (CHORUS)	2004-2010 	Phase 3 (E-switch-ic)	Adjuvant CP	Non-inferior OS (primary endpoint)Median OS: 24.1 vs 22.6 mo(HR 0.87, 95% CI 0.72-1.05)
Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 5 IV once on day 1
*Paclitaxel (Taxol) 175 mg/m2 IV once on day 1
21-day cycle for 3 cycles
====Subsequent treatment====
*Interval debulking surgery, then adjuvant CP x 3
===Regimen variant #2, AUC 5/175 x 6===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy 	Comparative Toxicity
Fagotti et al. 2016 (SCORPION)	2011-2014 	Phase 3 (E-switch-ic)	Adjuvant CP	Did not meet co-primary endpoint of PFS(HR not reported)	Better QoL (secondary endpoint)
Note: this was an experimental arm that did not meet its primary endpoint; included here because of the favorable QoL profile.
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 5 IV once on day 1
*Paclitaxel (Taxol) 175 mg/m2 IV once on day 1
21-day cycle for 6 cycles
====Subsequent treatment====
*Interval debulking surgery
===Regimen variant #3, AUC 6/175 x 3===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Vergote et al. 2010 (EORTC 55971)	1998-2006 	Phase 3 (E-switch-ic)	Adjuvant CP	Non-inferior OS (primary endpoint)Median OS: 30 vs 29 mo(HR 0.98, 90% CI 0.84-1.13)
Kehoe et al. 2015 (CHORUS) 	2004-2010 	Phase 3 (C) 	Adjuvant CP	Non-inferior OSMedian OS: 22.6 vs 24.1 mo(HR 1.15, 95% CI 0.95-1.39)
Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 6 IV once on day 1
*Paclitaxel (Taxol) 175 mg/m2 IV once on day 1
21-day cycle for 3 cycles
====Subsequent treatment====
*Interval debulking surgery, then adjuvant CP x 3
===References===
# EORTC 55971: Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; EORTC-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010 Sep 2;363(10):943-53. link to original article dosing details in supplement have been reviewed by our editors EuroPMC NCT00003636
# CHORUS: Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015 Jul 18;386(9990):249-57. Epub 2015 May 19. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC ISRCTN74802813
# SCORPION: Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, Costantini B, Margariti PA, Gueli Alletti S, Cosentino F, Tortorella L, Scambia G. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer. 2016 May;59:22-33. Epub 2016 Mar 19. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01461850
=First-line chemotherapy for advanced stage disease=
Note: in a majority of these regimens, chemotherapy was preceded by primary debulking surgery.
==Carboplatin monotherapy==
===Regimen variant #1, AUC 5===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy 	Comparative Toxicity
Parmar et al. 1998 (ICON2)	1991-1996 	Phase 3 (E-de-esc)	CAP 	Did not meet primary endpoint of OS	Less toxic
Parmar et al. 2002 (ICON3)	1995-1998 	Phase 3 (C) 	1. CAP2. Carboplatin & Paclitaxel	Did not meet primary endpoint of OS	
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 5 IV once on day 1
21-day cycle for 6 cycles
===Regimen variant #2, AUC 6, q3wk===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Parmar et al. 2002 (ICON3) 	1995-1998 	Phase 3 (C)	1. CAP2. Carboplatin & Paclitaxel	Did not meet primary endpoint of OS
Banerjee et al. 2012 (SCOTROC 4)	2004-2009 	Phase 3 (C)	Carboplatin; dose-escalated 	Did not meet primary endpoint of PFSMedian PFS: 12.1 vs 12.1 mo(HR 1.01, 95% CI 0.87-1.18)
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 6 IV once on day 1
21-day cycle for 6 cycles
===Regimen variant #3, AUC 6, q4wk===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Gore et al. 1998	1987-1995 	Phase 3 (C)	Carboplatin; AUC 12 x 4	Did not meet primary endpoint of OS24
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 6 IV once on day 1
28-day cycle for 6 cycles
===Regimen variant #4, AUC 9===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Markman et al. 2001 (GOG 114)	1992-1995 	Phase 3 (E-esc)	See link 	See link
Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.
====Preceding treatment====
*Primary debulking surgery, with optimal debulking
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 9 IV once on day 1
28-day cycle for 2 cycles
====Subsequent treatment====
*Adjuvant IP Cisplatin & IV Paclitaxel x 6
===Regimen variant #5, 400 mg/m2, q4wk===
Historic variant
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Taylor et al. 1994 	1981-10 to 1984-06 	Phase 3 (C)	Cisplatin 	Did not meet primary endpoint of ORR
Mangioni et al. 1989	1985-01 to 1987-02 	Phase 3 (C)	Cisplatin 	Did not meet endpoint
====Chemotherapy====
*Carboplatin (Paraplatin) 400 mg/m2 IV once on day 1
28-day cycle for 10 cycles
===References===
# Mangioni C, Bolis G, Pecorelli S, Bragman K, Epis A, Favalli G, Gambino A, Landoni F, Presti M, Torri W, Vassena L, Zanaboni F, Marsoni S. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst. 1989 Oct 4;81(19):1464-71. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# Taylor AE, Wiltshaw E, Gore ME, Fryatt I, Fisher C. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol. 1994 Oct;12(10):2066-70. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# Gore M, Mainwaring P, A'Hern R, MacFarlane V, Slevin M, Harper P, Osborne R, Mansi J, Blake P, Wiltshaw E, Shepherd J; London Gynaecological Oncology Group. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. J Clin Oncol. 1998 Jul;16(7):2426-34. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# ICON2: Parmar MKB, Torri V, Bonaventura A, Bonazzi C, Colombo N, Delaloye JF, Marsoni S, Mangioni C, Sandercock J, Sessa C, Williams C; ICON. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer: International Collaborative Ovarian Neoplasm Study. Lancet. 1998 Nov 14;352(9140):1571-6. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# GOG 114: Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Feb 15;19(4):1001-7. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# ICON3: Parmar MKB, Adams M, Balestrino M, Bertelsen K, Bonazzi C, Calvert H, Colombo N, Delaloye JF, Durando A, Guthrie D, Hagen B, Harper P, Mangioni C, Perren T, Poole C, Qian W, Rustin G, Sandercock J, Tumolo S, Torri V, Vecchione F; International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002 Aug 17;360(9332):505-15. Erratum in: Lancet. 2003 Feb 22;361(9358):706. link to original article EuroPMC
# SCOTROC 4: Banerjee S, Rustin G, Paul J, Williams C, Pledge S, Gabra H, Skailes G, Lamont A, Hindley A, Goss G, Gilby E, Hogg M, Harper P, Kipps E, Lewsley LA, Hall M, Vasey P, Kaye SB; GCIG. A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Ann Oncol. 2013 Mar;24(3):679-87. Epub 2012 Oct 5. link to original article link to PMC article dosing details in abstract have been reviewed by our editors EuroPMC NCT00098878
==Carboplatin & Docetaxel (DCb)==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Vasey et al. 2004 (SCOTROC-1)	1998-2000 	Phase 3 (E-switch-ic)	Carboplatin & Paclitaxel	Did not meet primary endpoint of PFS
====Preceding treatment====
*Primary debulking surgery
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 5 IV over 60 minutes once on day 1, given second
*Docetaxel (Taxotere) 75 mg/m2 IV over 60 minutes once on day 1, given first
====Supportive therapy====
*Dexamethasone (Decadron) 8 mg PO twice per day the day before, the day of, and day after docetaxel
*ONE of the following 5-HT3 antagonists:
**Ondansetron (Zofran) 8 mg
**Granisetron 3 mg
21-day cycle for 6 cycles
===References===
# SCOTROC-1: Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB; Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00003998
==Carboplatin & Pegylated liposomal doxorubicin==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Pignata et al. 2006 (MITO-2)	2003-2007 	Phase 3 (E-switch-ic)	Carboplatin & Paclitaxel	Did not meet primary endpoint of PFS1Median PFS: 19 vs 16.8 mo(HR 0.95, 95% CI 0.81-1.13)
1Reported efficacy is based on the 2011 update.
====Eligibility criteria====
*Cytologic or histologic diagnosis of epithelial ovarian cancer (stage IC to IV according to International Federation of Gynecology and Obstetrics staging system)
====Preceding treatment====
*Primary debulking surgery
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 5 IV over 30 minutes once on day 1, given first
*Pegylated liposomal doxorubicin (Doxil) 30 mg/m2 IV over 60 minutes once on day 1, given second
====Supportive therapy====
*"No prophylactic use of G-CSF was recommended. Therapeutic and prophylactic use of G-CSF was allowed for febrile or afebrile grade 4 neutropenia."
21-day cycle for 3 to 6 cycles 
All patients received 3 cycles of therapy. Patients with stable or responsive disease received an additional 3 cycles.
===References===
# MITO-2: Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F; MITO. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer. 2006 Aug 1;6:202. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00326456
## Update: Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F, Di Maio M, Morabito A, Gallo C, Perrone F. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol. 2011 Sep 20;29(27):3628-35. Epub 2011 Aug 15. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Carboplatin & Gemcitabine (GCb)==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Gordon et al. 2011 (B9E-US-S302)	2002-2006 	Phase 3 (E-switch-ic)	Carboplatin & Paclitaxel	Did not meet primary endpoint of PFSMedian PFS: 20 vs 22.2 mo
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 5 IV over 30 minutes once on day 1, given second
*Gemcitabine (Gemzar) 1000 mg/m2 IV over 30 minutes once per day on days 1 & 8, given first
21-day cycle for up to 6 cycles
====Subsequent treatment====
*B9E-US-S302, patients with CR: optional paclitaxel consolidation
===References===
# B9E-US-S302: Gordon AN, Teneriello M, Janicek MF, Hines J, Lim PC, Chen MD, Vaccarello L, Homesley HD, McMeekin S, Burkholder TL, Wang Y, Zhao L, Orlando M, Obasaju CK, Gill JF, Tai DF. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer. Gynecol Oncol. 2011 Dec;123(3):479-85. Epub 2011 Oct 5. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00191646
==Carboplatin & Paclitaxel (CP)==
TC: Taxol (Paclitaxel) & Carboplatin
PC: Paclitaxel & Carboplatin
===Regimen variant #1, q1wk AUC 2/60===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Pignata et al. 2014 (MITO-7)	2008-2012 	Phase 3 (E-switch-ic)	TC; q3wk AUC 6/175	Did not meet primary endpoint of PFSMedian PFS: 18.3 vs 17.3 mo(HR 1.04, 95% CI 0.86-1.25)
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 2 IV once on day 1
*Paclitaxel (Taxol) 60 mg/m2 IV once on day 1
7-day cycle for 18 cycles 
===Regimen variant #2, q3wk AUC 5, q1wk 80===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Monk et al. 2021 (JAVELIN Ovarian 100)	2016-2018 	Phase 3 (C)	1. CP & Avelumab2. CP, then Avelumab	Did not meet primary endpoint of PFS
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 5 IV once on day 1
*Paclitaxel (Taxol) 80 mg/m2 IV once per day on days 1, 8, 15
21-day cycle for 6 cycles
===Regimen variant #3, q3wk AUC 5/175===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy 	Comparative Toxicity
Neijt et al. 2000 	1994-1997 	Phase 3 (E-switch-ic)	Cisplatin & Paclitaxel 	Did not meet primary endpoint of PFS 	
du Bois et al. 2006 (AGO-OVAR 5) 	1997-2000 	Phase 3 (C) 	TEC 	Did not meet primary endpoint of OS 	
Vasey et al. 2004 (SCOTROC-1) 	1998-2000 	Phase 3 (C) 	Carboplatin & Docetaxel 	Did not meet primary endpoint of PFS 	
Möbus et al. 2007 (HIDOC-EIS) 	1998-2004 	Phase 3 (C) 	High-dose chemotherapy with auto HSCT 	Did not meet primary endpoint of PFS 	
Lindemann et al. 2012 (EORTC 55981) 	1999-2001 	Phase 3 (C) 	TEC 	Did not meet primary endpoint of PFS 	
Hoskins et al. 2010 (EORTC 55012) 	2001-2005 	Phase 3 (C) 	Cisplatin & Topotecan, then TC 	Did not meet primary endpoint of PFSMedian PFS: 16.2 vs 14.6 mo(HR 0.91, 95% CI 0.78-1.06)	Less toxic
du Bois et al. 2010 (AGO-OVAR 9) 	2002-2004 	Phase 3 (C) 	TCG 	Did not meet primary endpoint of OSMedian OS: 51.5 vs 49.5 mo(HR 0.95, 95% CI 0.83-1.10) 	
Pignata et al. 2006 (MITO-2) 	2003-2007 	Phase 3 (C) 	Carboplatin & PLD 	Did not meet primary endpoint of PFS1Median PFS: 16.8 vs 19 mo(HR 1.05, 95% CI 0.88-1.23) 	
du Bois et al. 2015 (AGO-OVAR 12) 	2009-2011 	Phase 3 (C) 	TC & Nintedanib 	Seems to have shorter PFSMedian PFS: 16.6 vs 17.2 mo(HR 1.19, 95% CI 1.02-1.39) 	
Fagotti et al. 2016 (SCORPION) 	2011-2014 	Phase 3 (C) 	TC; neoadjuvant 	Did not meet co-primary endpoint of PFS 	Worse QoL
Clamp et al. 2019 (ICON8) 	2011-2014 	Phase 3 (C) 	1. TC; q1wk AUC 2/802. TC; q3wk AUC 6, q1wk 80 ("dose-dense")	Did not meet co-primary endpoints of PFS/OS 	
Vergote et al. 2019 (TRINOVA-3) 	2012-2014 	Phase 3 (C) 	TC & Trebananib 	Did not meet primary endpoint of PFSMedian PFS: 15 vs 15.9 mo(HR 1.08, 95% CI 0.92-1.27) 	
Monk et al. 2021 (JAVELIN Ovarian 100)	2016-2018 	Phase 3 (C) 	1. CP & Avelumab2. CP, then Avelumab 	Did not meet primary endpoint of PFS 	
1Reported efficacy for MITO-2 is based on the 2011 update.
Note: In MITO-2, all patients received 3 cycles of therapy. Patients with stable or responsive disease received an additional 3 cycles.
====Preceding treatment====
*Neijt et al. 2000: Primary debulking surgery was recommended
*SCOTROC-1, MITO-2, AGO-OVAR 12, SCORPION: Primary debulking surgery
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 5 IV over 30 to 60 minutes once on day 1, given second
*Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1, given first
====Supportive therapy====
*(per Vasey et al. 2004):
*Dexamethasone (Decadron) 20 mg PO twice on day 1, given 12 and 6 hours prior to paclitaxel
*One of the following antihistamines:
**Diphenhydramine (Benadryl) 50 mg IV once on day 1, given 30 minutes prior to paclitaxel
**Chlorpheniramine (Chlor-Trimeton) 10 mg IV once on day 1, given 30 minutes prior to paclitaxel
*One of the following H2-blockers
**Ranitidine (Zantac) 50 mg IV once on day 1, given 30 minutes prior to paclitaxel
**Cimetidine (Tagamet) 300 mg IV once on day 1, given 30 minutes prior to paclitaxel
*One of the following serotonin 5-HT3 antagonists:
**Ondansetron (Zofran) 8 mg
**Granisetron 3 mg
21-day cycle for varying durations: 3 to 6 cycles (MITO-2); 6 cycles (AGO-OVAR 12, HIDOC-EIS, ICON8, JAVELIN Ovarian 100, SCORPION, TRINOVA-3); at least 6 cycles (AGO-OVAR 5, AGO-OVAR 9, Neijt et al. 2000); 6 to 9 cycles (EORTC 55981, SCOTROC-1); 8 cycles (EORTC 55012)
===Regimen variant #4, q3wk AUC 6, q1wk 80===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Katsumata et al. 2009 (JGOG 3016) 	2003-2005 	Phase 3 (E-switch-ic)	TC; q3wk AUC 6/180 	Seems to have longer OS (secondary endpoint)OS36: 72.1% vs 65.1%(HR 0.75, 95% CI 0.57-0.98)Longer PFS (primary endpoint)Median PFS: 28 vs 17.2 mo(HR 0.71, 95% CI 0.58-0.88)
Coleman et al. 2019 (VELIA) 	2015-2017 	Phase 3 (C) 	1. CP & Veliparib x 6 	Not reported
Coleman et al. 2019 (VELIA) 	2015-2017 	Phase 3 (C) 	2. CP & Veliparib x 6, then Veliparib maint.	Shorter PFS (primary endpoint)Median PFS: 17.3 vs 23.5 mo(HR 1.47, 95% CI 1.20-1.79)
Monk et al. 2021 (JAVELIN Ovarian 100)	2016-2018 	Phase 3 (C) 	1. CP & Avelumab2. CP, then Avelumab 	Did not meet primary endpoint of PFS
Nagao et al. 2023 (iPocc) 	2010-05 to 2016-08 	Phase 2/3 (C) 	IP Carboplatin & Paclitaxel 	Seems to have shorter PFSMedian PFS: 20.7 vs 23.5 mo(HR 1.20, 95% CI 1.01-1.45)
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 6 IV over 60 minutes once on day 1
*Paclitaxel (Taxol) 80 mg/m2 IV over 60 minutes once per day on days 1, 8, 15
====Supportive therapy====
*"Standard premedication"
21-day cycle for varying durations: 6 cycles (iPocc, JAVELIN Ovarian 100, VELIA); 6 to 9 cycles (JGOG 3016)
===Regimen variant #5, q3wk AUC 6/175===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Lhommé et al. 2008 	1997-1999 	Phase 3 (C)	Paclitaxel & Valspodar 	Did not meet primary endpoint of TTPMedian TTP: 13.5 vs 13.2 mo
Vergote et al. 2010 (EORTC 55971) 	1998-2006 	Phase 3 (C)	TC x 3, then interval debulking, then TC x 3 	Non-inferior OS
Gordon et al. 2011 (B9E-US-S302) 	2002-2006 	Phase 3 (C)	Carboplatin & Gemcitabine 	Did not meet primary endpoint of PFS
Bookman et al. 2009 (ICON5) 	2001-2004 	Phase 3 (C)	1. TCG2. TC & PLD3. TC & Topotecan 	Did not meet primary endpoint of OS
Alberts et al. 2008 (GRACES) 	2002-2004 	Phase 3 (C)	CP & IFN gamma-1b 	Longer OS (primary endpoint)Median OS: NYR vs 1138 d(HR 0.69, 95% CI 0.55-0.87)
Burger et al. 2011 (GOG-0218) 	2005-2009 	Phase 3 (C)	1. TC & Bevacizumab x 6 	Might have shorter PFS
Burger et al. 2011 (GOG-0218) 	2005-2009 	Phase 3 (C)	2. TC & Bevacizumab x 22 	Shorter PFS
Perren et al. 2011 (ICON7) 	2006-2009 	Phase 3 (C)	CP & Bevacizumab 	Did not meet co-primary endpoints of PFS/OS1
Sugiyama et al. 2016 (JGOG3017/GCIG) 	2006-2011 	Phase 3 (C)	Cisplatin & Irinotecan 	Did not meet primary endpoint of PFSPFS24: 77.6% vs 73%(HR 0.85, 95% CI 0.63-1.15)
Pignata et al. 2014 (MITO-7) 	2008-2012 	Phase 3 (C)	TC; q1wk AUC 2/60 	Did not meet primary endpoint of PFSMedian PFS: 17.3 vs 18.3 mo(HR 0.96, 95% CI 0.80-1.16)
du Bois et al. 2015 (AGO-OVAR 12) 	2009-2011 	Phase 3 (C)	TC & Nintedanib 	Seems to have shorter PFSMedian PFS: 16.6 vs 17.2 mo(HR 1.19, 95% CI 1.02-1.39)
Chan et al. 2016 (GOG-0262) 	2010-2012 	Phase 3 (C)	TC; dose-dense 	Did not meet primary endpoint of PFSMedian PFS: 14 vs 14.7 mo(HR 1.12, 95% CI 0.94-1.35)
Clamp et al. 2019 (ICON8) 	2011-2014 	Phase 3 (C)	1. TC; q1wk AUC 2/802. TC; q3wk AUC 6, q1wk 80 ("dose-dense")	Did not meet co-primary endpoints of PFS/OS
Vergote et al. 2019 (TRINOVA-3) 	2012-2014 	Phase 3 (C)	TC & Trebananib 	Did not meet primary endpoint of PFSMedian PFS: 15 vs 15.9 mo(HR 1.08, 95% CI 0.92-1.27)
Coleman et al. 2019 (VELIA) 	2015-2017 	Phase 3 (C)	1. TC & Veliparib x 6 	Not reported
Coleman et al. 2019 (VELIA) 	2015-2017 	Phase 3 (C)	2. TC & Veliparib x 6, then Veliparib maint. 	Shorter PFS (primary endpoint)Median PFS: 17.3 vs 23.5 mo(HR 1.47, 95% CI 1.20-1.79)
Monk et al. 2021 (JAVELIN Ovarian 100)	2016-2018 	Phase 3 (C)	1. CP & Avelumab2. CP, then Avelumab 	Did not meet primary endpoint of PFS
Wu et al. 2024 (YO40268) 	2018-08-15 to 2019-12-25	Phase 3 (C)	CP & Bevacizumab 	Shorter PFSMedian PFS: 12.3 vs 22.6 mo(HR 3.33, 95% CI 1.89-5.88)
1Reported efficacy for ICON7 is based on the 2015 update.
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 6 IV over 30 minutes once on day 1
*Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
21-day cycle for varying durations: 6 cycles (AGO-OVAR 12, B9E-US-S302, GOG-0218, GOG-0262, GRACES, ICON7, ICON8, JAVELIN Ovarian 100, JGOG3017/GCIG, MITO-7, TRINOVA-3, VELIA, YO40268); 6 to 9 cycles (Lhommé et al. 2008); at least 6 cycles (EORTC 55971); 8 cycles (ICON5)
====Subsequent treatment====
*B9E-US-S302, patients with CR: Optional paclitaxel consolidation
===Regimen variant #6, q3wk AUC 6/180===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Katsumata et al. 2009 (JGOG 3016)	2003-2005 	Phase 3 (C)	TC; dose-dense	Seems to have shorter OS (secondary endpoint)OS36: 65.1% vs 72.1%(HR 1.33, 95% CI 1.02-1.75)Shorter PFS (primary endpoint)Median PFS: 17.2 vs 28 mo(HR 1.41, 95% CI 1.14-1.72)
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 6 IV over 60 minutes once on day 1
*Paclitaxel (Taxol) 180 mg/m2 IV over 3 hours once on day 1
====Supportive therapy====
*"Standard premedication"
21-day cycle for 6 to 9 cycles, depending on response
===Regimen variant #7, AUC 6/185===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy	Comparative Toxicity
du Bois et al. 2003 (AGO-OVAR 3)	1995-1997 	Phase 3 (E-switch-ic)	Cisplatin & Paclitaxel	Non-inferior PFS 	Better QoL
====Preceding treatment====
*Primary debulking surgery
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 6 IV over 30 to 60 minutes once on day 1, given second
*Paclitaxel (Taxol) 185 mg/m2 (maximum dose of 400 mg) IV over 3 hours once on day 1, given first
21-day cycle for 6 or more cycles
===Regimen variant #8, q3wk AUC 7/175===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Aravantinos et al. 2005	1995-1999 	Phase 3 (C)	CP/Cisplatin & Paclitaxel 	Did not meet primary endpoint of OS
Aravantinos et al. 2008	1999-2004 	Phase 3 (C)	Cisplatin, Doxorubicin, Paclitaxel	Did not meet primary endpoint of OS
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 7 IV once on day 1
*Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
21-day cycle for 6 cycles
===Regimen variant #9, q3wk AUC 7.5/175===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Ozols et al. 2003 (GOG 158)	Not reported 	Phase 3 (E-switch-ic)	Cisplatin & Paclitaxel	Seems to have non-inferior RFS (primary endpoint)
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 7.5 IV once on day 1
*Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
====Supportive therapy====
*Dexamethasone (Decadron) with one of the following options:
**20 mg PO twice on day 1, given 12 and 6 hours prior to chemotherapy
**20 mg IV once on day 1, given 30 minutes prior to paclitaxel
*Diphenhydramine (Benadryl) 50 mg IV once on day 1, given 30 minutes prior to paclitaxel
*Cimetidine (Tagamet) 300 mg IV once on day 1, given 30 minutes prior to paclitaxel
21-day cycle for 6 cycles
===References===
# Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B, van Houwelingen HC. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000 Sep;18(17):3084-92. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# GOG 158: Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003 Sep 1;21(17):3194-200. Epub 2003 Jul 14. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# AGO-OVAR 3: du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J; Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# SCOTROC-1: Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB; Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00003998
# Aravantinos G, Fountzilas G, Kosmidis P, Dimopoulos MA, Stathopoulos GP, Pavlidis N, Bafaloukos D, Papadimitriou C, Karpathios S, Georgoulias V, Papakostas P, Kalofonos HP, Grimani E, Skarlos DV; Hellenic Cooperative Oncology Group. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol. 2005 Jul;16(7):1116-22. Epub 2005 May 31. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# AGO-OVAR 5: du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, Barats JC, Kuhn W, Orfeuvre H, Wagner U, Richter B, Lueck HJ, Pfisterer J, Costa S, Schroeder W, Kimmig R, Pujade-Lauraine E; Arbeitsgemeinschaft Gynaekologische Onkologie; Ovarian Cancer Study Group; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol. 2006 Mar 1;24(7):1127-35. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# HIDOC-EIS: Möbus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, Ostermann H, Hinke A, Ledermann JA; AGO-OVAR; AIO; EBMT. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol. 2007 Sep 20;25(27):4187-93. Epub 2007 Aug 13. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00004921
# MITO-2: Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F; MITO. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer. 2006 Aug 1;6:202. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00326456
## Update: Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P, Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F, Di Maio M, Morabito A, Gallo C, Perrone F. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol. 2011 Sep 20;29(27):3628-35. Epub 2011 Aug 15. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# GRACES: Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, Bradford WZ, Loutit J, Kirn DH, Clouser MC, Markman M; GRACES Clinical Trial Consortium. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol Oncol. 2008 May;109(2):174-81. Epub 2008 Mar 7. link to original article EuroPMC
# Lhommé C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, Baekelandt MM, Gordon AN, Fracasso PM, Mietlowski WL, Jones GJ, Dugan MH. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol. 2008 Jun 1;26(16):2674-82. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Aravantinos G, Fountzilas G, Bamias A, Grimani I, Rizos S, Kalofonos HP, Skarlos DV, Economopoulos T, Kosmidis PA, Stathopoulos GP, Briasoulis E, Pectasides D, Samantas E, Timotheadou E, Papadimitriou C, Papanikolaou A, Onyenadum A, Papakostas P, Bafaloukos D, Dimopoulos MA; Hellenic Cooperative Oncology Group. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Cancer. 2008 Oct;44(15):2169-77. Epub 2008 Aug 6. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# ICON5: Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM; Gynecologic Cancer Intergroup. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009 Mar 20;27(9):1419-25. Epub 2009 Feb 17. Erratum in: J Clin Oncol. 2009 May 1;27(13):2305. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00011986
# JGOG 3016: Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K; Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Oct 17;374(9698):1331-8. Epub 2009 Sep 18. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00226915
## Update: Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, Sugiyama T, Ochiai K; Japanese Gynecologic Oncology Group. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013 Sep;14(10):1020-6. Epub 2013 Aug 13. link to original article EuroPMC
# AGO-OVAR 9: du Bois A, Herrstedt J, Hardy-Bessard AC, Müller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol. 2010 Sep 20;28(27):4162-9. Epub 2010 Aug 23. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT00052468
# EORTC 55971: Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; EORTC-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010 Sep 2;363(10):943-53. link to original article dosing details in supplement have been reviewed by our editors EuroPMC NCT00003636
# EORTC 55012: Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst. 2010 Oct 20;102(20):1547-56. Epub 2010 Oct 11. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT00028743
# B9E-US-S302: Gordon AN, Teneriello M, Janicek MF, Hines J, Lim PC, Chen MD, Vaccarello L, Homesley HD, McMeekin S, Burkholder TL, Wang Y, Zhao L, Orlando M, Obasaju CK, Gill JF, Tai DF. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer. Gynecol Oncol. 2011 Dec;123(3):479-85. Epub 2011 Oct 5. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00191646
# GOG-0218: Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2473-83. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00262847
##PRO analysis: Monk BJ, Huang HQ, Burger RA, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Liang SX, Wenzel L. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2013 Mar;128(3):573-8. Epub 2012 Dec 4. link to original article link to PMC article EuroPMC
## Update: Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol. 2019 Sep 10;37(26):2317-2328. Epub 2019 Jun 19. link to original article link to PMC article EuroPMC
# ICON7: Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484-96. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00483782
##HRQoL analysis: Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013 Mar;14(3):236-43. Epub 2013 Jan 18. link to original article link to PMC article EuroPMC
## Update: Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015 Aug;16(8):928-36. Epub 2015 Jun 23. link to original article link to PMC article EuroPMC
# EORTC 55981: Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kærn J, Havsteen H, Eisenhauer E, Ridderheim M, Lopez AB, Hirte H, Aavall-Lundquvist E, Vrdoljak E, Green J, Kristensen GB; Gynecologic Cancer Intergroup. First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG and NCIC-CTG. Ann Oncol. 2012 Oct;23(10):2613-9. Epub 2012 Apr 26. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT00004934
# MITO-7: Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; MITO; GINECO; Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups; Gynecologic Cancer Intergroup. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014 Apr;15(4):396-405. Epub 2014 Feb 28. link to original article EuroPMC NCT00660842
# CHORUS: Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015 Jul 18;386(9990):249-57. Epub 2015 May 19. link to original article EuroPMC ISRCTN74802813
# AGO-OVAR 12: du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2016 Jan;17(1):78-89. Epub 2015 Nov 16. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01015118
## Update: Ray-Coquard I, Cibula D, Mirza MR, Reuss A, Ricci C, Colombo N, Koch H, Goffin F, González-Martin A, Ottevanger PB, Baumann K, Bjørge L, Lesoin A, Burges A, Rosenberg P, Gropp-Meier M, Harrela M, Harter P, Frenel JS, Minarik T, Pisano C, Hasenburg A, Merger M, du Bois A; AGO Study Group-led GCIG/ENGOT Intergroup Consortium. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. Int J Cancer. 2020 Jan 15;146(2):439-448. Epub 2019 Sep 6. link to original article EuroPMC
# GOG-0262: Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016 Feb 25;374(8):738-48. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01167712
# SCORPION: Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, Costantini B, Margariti PA, Gueli Alletti S, Cosentino F, Tortorella L, Scambia G. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer. 2016 May;59:22-33. Epub 2016 Mar 19. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01461850
# JGOG3017: Sugiyama T, Okamoto A, Enomoto T, Hamano T, Aotani E, Terao Y, Suzuki N, Mikami M, Yaegashi N, Kato K, Yoshikawa H, Yokoyama Y, Tanabe H, Nishino K, Nomura H, Kim JW, Kim BG, Pignata S, Alexandre J, Green J, Isonishi S, Terauchi F, Fujiwara K, Aoki D. Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017/GCIG trial. J Clin Oncol. 2016 Aug 20;34(24):2881-7. Epub 2016 Jul 11. link to original article dosing details in abstract have been reviewed by our editors EuroPMC UMIN000000499
# TRINOVA-3: Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019 Jun;20(6):862-876. Epub 2019 May 7. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01493505
# VELIA: Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2403-2415. Epub 2019 Sep 28. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT02470585
# ICON8: Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, Hook J, Coyle C, Blagden S, Brenton JD, Naik R, Perren T, Sundar S, Cook AD, Gopalakrishnan GS, Gabra H, Lord R, Dark G, Earl HM, Hall M, Banerjee S, Glasspool RM, Jones R, Williams S, Swart AM, Stenning S, Parmar M, Kaplan R, Ledermann JA. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet. 2019 Dec 7;394(10214):2084-2095. Epub 2019 Nov 29. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT01654146
##HRQoL analysis: Blagden SP, Cook AD, Poole C, Howells L, McNeish IA, Dean A, Kim JW, O'Donnell DM, Hook J, James EC, White IR, Perren T, Lord R, Dark G, Earl HM, Hall M, Kaplan R, Ledermann JA, Clamp AR. Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncol. 2020 Jul;21(7):969-977. link to original article link to PMC article EuroPMC
##Update: Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, Gallardo-Rincon D, Blagden S, Brenton J, Perren TJ, Sundar S, Lord R, Dark G, Hall M, Banerjee S, Glasspool RM, Hanna CL, Williams S, Scatchard KM, Nam H, Essapen S, Parkinson C, McAvan L, Swart AM, Popoola B, Schiavone F, Badrock J, Fananapazir F, Cook AD, Parmar M, Kaplan R, Ledermann JA. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2022 Jul;23(7):919-930. Epub 2022 Jun 8. link to original article link to PMC article EuroPMC
# JAVELIN Ovarian 100: Monk BJ, Colombo N, Oza AM, Fujiwara K, Birrer MJ, Randall L, Poddubskaya EV, Scambia G, Shparyk YV, Lim MC, Bhoola SM, Sohn J, Yonemori K, Stewart RA, Zhang X, Perkins Smith J, Linn C, Ledermann JA. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Sep;22(9):1275-1289. Epub 2021 Aug 4. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT02718417
#iPocc: Nagao S, Fujiwara K, Yamamoto K, Tanabe H, Okamoto A, Takehara K, Saito M, Fujiwara H, Tan DSP, Yamaguchi S, Adachi S, Kikuchi A, Hirasawa T, Yokoi T, Nagai T, Sato T, Kamiura S, Fujishita A, Loong W-W, Chan K, Syks P, Olawaye A, Ryu S-Y, Shigeta H, Kondo E, Yokoyama Y, Matsumoto T, Hasegawa K, Enomoto T. Intraperitoneal Carboplatin for Ovarian Cancer - A Phase 2/3 Trial. NEJM Evid. 2023;2(5). link to original article dosing details in supplement have been reviewed by our editors EuroPMC jRCTs031180141
#YO40268: Wu X, Liu J, An R, Yin R, Zhang Y, Zhou H, He A, Wang L, Zhang J, Liu Z, Duan W, Zhu J, Lou G, Chen G, Cheng Y, Xue F, Nick S, Wang H, Li D. First-line bevacizumab plus chemotherapy in Chinese patients with stage III/IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: a phase III randomized controlled trial. J Gynecol Oncol. 2024 Sep;35(5):e99. Epub 2024 Apr 22. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT03635489
# FLORA-5: NCT04498117
# KEYLYNK-001: NCT03740165
==Carboplatin & Paclitaxel (CP) & Bevacizumab==
TC-BEV: Taxol (Paclitaxel), Carboplatin, BEVacizumab
===Regimen variant #1, q3wk paclitaxel, standard-dose bevacizumab x 6===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Burger et al. 2011 (GOG-0218)	2005-2009 	Phase 3 (E-RT-esc)	1. Carboplatin & Paclitaxel 	Might have longer PFS (primary endpoint)Median PFS: 11.2 vs 10.3 mo(HR 0.91, 95% CI 0.80-1.04)Did not meet secondary endpoint of OS1Median OS: 40.8 vs 41.1 mo(HR 1.06, 95% CI 0.94-1.20)
Burger et al. 2011 (GOG-0218)	2005-2009 	Phase 3 (E-RT-esc)	2. CP & Bevacizumab x 22 	Not reported
Chan et al. 2016 (GOG-0262) 	2010-2012 	Phase 3 (C) 	TC-Bev; dose-dense 	Did not meet primary endpoint of PFSMedian PFS: 14 vs 14.7 mo(HR 1.12, 95% CI 0.94-1.35)
Moore et al. 2021 (IMagyn050)	2017-2019 	Phase 3 (C) 	CP, Atezolizumab, Bevacizumab	Did not meet primary endpoint of PFSMedian PFS: 18.4 vs 19.5 mo(HR 1.09, 95% CI 0.93-1.27)
1Reported efficacy for OS in this arm of GOG-0218 is based on the 2019 update.
Note: The decision to use bevacizumab in GOG-0262 was at the discretion of the patient; it was not a randomization.
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 6 IV over 30 minutes once on day 1
*Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
====Targeted therapy====
*Bevacizumab (Avastin) as follows:
**Cycles 2 to 6: 15 mg/kg IV once on day 1
21-day cycle for 6 cycles
====Subsequent treatment====
*GOG-0262 & IMagyn050: Bevacizumab maintenance
===Regimen variant #2, q3wk paclitaxel, standard-dose bevacizumab x 22===
FDA-recommended dose
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Burger et al. 2011 (GOG-0218)	2005-2009 	Phase 3 (E-RT-esc)	1. Carboplatin & Paclitaxel	Longer PFS (primary endpoint)Median PFS: 14.1 vs 10.3 mo(HR 0.72, 95% CI 0.625-0.82)Did not meet secondary endpoint of OS1Median OS: 43.4 vs 41.1 mo(HR 0.96, 95% CI 0.85-1.09)
Burger et al. 2011 (GOG-0218)	2005-2009 	Phase 3 (E-RT-esc)	2. CP & Bevacizumab x 6 	Not reported
Wu et al. 2024 (YO40268) 	2018-08-15 to 2019-12-25	Phase 3 (E-esc) 	CP 	Longer PFS (primary endpoint)Median PFS: 22.6 vs 12.3 mo(HR 0.30, 95% CI 0.17-0.53)
1Reported efficacy for OS in this arm of GOG-0218 is based on the 2019 update.
====Chemotherapy====
*Carboplatin (Paraplatin) as follows:
**Cycles 1 to 6: AUC 6 IV over 30 minutes once on day 1
*Paclitaxel (Taxol) as follows:
**Cycles 1 to 6: 175 mg/m2 IV over 3 hours once on day 1
====Targeted therapy====
*Bevacizumab (Avastin) as follows:
**Cycles 2 to 22: 15 mg/kg IV once on day 1
21-day cycle for 22 cycles
===Regimen variant #3, q3wk paclitaxel, low-dose bevacizumab===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Perren et al. 2011 (ICON7)	2006-2009 	Phase 3 (E-esc)	Carboplatin & Paclitaxel	Did not meet co-primary endpoint of OS1RMST: 45.5 vs 44.6 mo(RMST difference 0.9 mo, 95% CI -0.8 to 2.6 mo)Did not meet co-primary endpoint of PFS1RMST: 19.9 vs 17.5 mo(RMST difference 1.6 mo, 95% CI -0.6 to 3.7 mo)
1Reported efficacy is based on the 2015 update.
Note: Bevacizumab was not given with cycle 1 if chemotherapy starts within 4 weeks of surgery. The protocol linked from Perren et al. 2011 clarified that the recommended carboplatin dose was AUC 6, but that it could be adjusted per standard practice
====Chemotherapy====
*Carboplatin (Paraplatin) as follows:
**Cycles 1 to 6: AUC 5 to 6 IV over 30 to 60 minutes once on day 1
*Paclitaxel (Taxol) as follows:
**Cycles 1 to 6: 175 mg/m2 IV over 3 hours once on day 1
====Targeted therapy====
*Bevacizumab (Avastin) as follows:
**Cycles 1 to 6: 7.5 mg/kg IV once on day 1
**Cycles 7 to 18: 15 mg/kg IV once on day 1
21-day cycle for 18 cycles
===Regimen variant #4, weekly paclitaxel===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Walker et al. 2019 (GOG-252)	2009-2011 	Phase 3 (C)	1. IP Carboplatin, IV Paclitaxel & Bevacizumab2. IP Cisplatin & Paclitaxel, IV Paclitaxel & Bevacizumab	Did not meet primary endpoint of PFS
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 6 IV once on day 1
*Paclitaxel (Taxol) 80 mg/m2 IV once per day on days 1, 8, 15
====Targeted therapy====
*Bevacizumab (Avastin) as follows:
**Cycles 2 to 6: 15 mg/kg IV once on day 1
21-day cycle for 6 cycles
====Subsequent treatment====
*Bevacizumab maintenance
===References===
# GOG-0218: Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2473-83. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00262847
##PRO analysis: Monk BJ, Huang HQ, Burger RA, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Liang SX, Wenzel L. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2013 Mar;128(3):573-8. Epub 2012 Dec 4. link to original article link to PMC article EuroPMC
## Update: Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol. 2019 Sep 10;37(26):2317-2328. Epub 2019 Jun 19. link to original article link to PMC article EuroPMC
# ICON7: Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484-96. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00483782
##HRQoL analysis: Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013 Mar;14(3):236-43. Epub 2013 Jan 18. link to original article link to PMC article EuroPMC
## Update: Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015 Aug;16(8):928-36. Epub 2015 Jun 23. link to original article link to PMC article EuroPMC
# GOG-0262: Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016 Feb 25;374(8):738-48. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01167712
# GOG-252: Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, Fujiwara K, Alberts DS, Zheng W, Tewari KS, Cohn DE, Powell MA, Van Le L, Davidson SA, Gray HJ, Rose PG, Aghajanian C, Myers T, Alvarez Secord A, Rubin SC, Mannel RS. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2019 Jun 1;37(16):1380-1390. Epub 2019 Apr 19. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00951496
# IMagyn050: Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, Myers T, Taskiran C, Robison K, Mäenpää J, Willmott L, Colombo N, Thomes-Pepin J, Liontos M, Gold MA, Garcia Y, Sharma SK, Darus CJ, Aghajanian C, Okamoto A, Wu X, Safin R, Wu F, Molinero L, Maiya V, Khor VK, Lin YG, Pignata S. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021 Jun 10;39(17):1842-1855. Epub 2021 Apr 23. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT03038100
##Update: Pignata S, Bookman M, Sehouli J, Miller A, Penson RT, Taskiran C, Anderson C, Hietanen S, Myers T, Madry R, Willmott L, Lortholary A, Thomes-Pepin J, Aghajanian C, McCourt C, Stuckey A, Wu X, Nishio S, Copeland LJ, He Y, Molinero L, Patel S, Lin YG, Khor VK, Moore KN. Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer. Gynecol Oncol. 2023 Oct;177:20-31. Epub 2023 Aug 23. link to original article link to PMC article EuroPMC
#YO40268: Wu X, Liu J, An R, Yin R, Zhang Y, Zhou H, He A, Wang L, Zhang J, Liu Z, Duan W, Zhu J, Lou G, Chen G, Cheng Y, Xue F, Nick S, Wang H, Li D. First-line bevacizumab plus chemotherapy in Chinese patients with stage III/IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: a phase III randomized controlled trial. J Gynecol Oncol. 2024 Sep;35(5):e99. Epub 2024 Apr 22. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT03635489
#DUO-O: NCT03737643
# FIRSTOV: NCT03602859
==Carboplatin & Paclitaxel (CP) & Nintedanib==
CP & Nintedanib: Carboplatin, Paclitaxel, Nintedanib
TC & Nintedanib: Taxol (Paclitaxel), Carboplatin, Nintedanib
===Regimen variant #1, q3wk AUC 5/175===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
du Bois et al. 2015 (AGO-OVAR 12)	2009-2011 	Phase 3 (E-esc)	TC 	Seems to have longer PFS (primary endpoint)Median PFS: 17.2 vs 16.6 mo(HR 0.84, 95% CI 0.72-0.98)
====Preceding treatment====
*Primary debulking surgery
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 5 IV over 60 minutes once on day 1, given second
*Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1, given first
====Targeted therapy====
*Nintedanib (Vargatef) 200 mg PO twice per day on days 2 to 21
21-day cycles
===Regimen variant #2, q3wk AUC 6/175===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
du Bois et al. 2015 (AGO-OVAR 12)	2009-2011 	Phase 3 (E-esc)	TC 	Seems to have longer PFS (primary endpoint)Median PFS: 17.2 vs 16.6 mo(HR 0.84, 95% CI 0.72-0.98)
====Preceding treatment====
*Primary debulking surgery
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 6 IV over 60 minutes once on day 1, given second
*Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1, given first
====Targeted therapy====
*Nintedanib (Vargatef) 200 mg PO twice per day on days 2 to 21
21-day cycles
===References===
# AGO-OVAR 12: du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2016 Jan;17(1):78-89. Epub 2015 Nov 16. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01015118
## Update: Ray-Coquard I, Cibula D, Mirza MR, Reuss A, Ricci C, Colombo N, Koch H, Goffin F, González-Martin A, Ottevanger PB, Baumann K, Bjørge L, Lesoin A, Burges A, Rosenberg P, Gropp-Meier M, Harrela M, Harter P, Frenel JS, Minarik T, Pisano C, Hasenburg A, Merger M, du Bois A; AGO Study Group-led GCIG/ENGOT Intergroup Consortium. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. Int J Cancer. 2020 Jan 15;146(2):439-448. Epub 2019 Sep 6. link to original article EuroPMC
==Cisplatin & Paclitaxel (TP)==
TP: Taxol (Paclitaxel) & Platinol (Cisplatin)
PT: Platinol (Cisplatin) & Taxol (Paclitaxel)
===Regimen variant #1, 75/135===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
McGuire et al. 1996 (GOG 111) 	Not reported 	Phase 3 (E-RT-switch-ic)	Cisplatin & Cyclophosphamide 	Longer OSMedian OS: 38 vs 24 mo(RR 0.60, 95% CI 0.50-0.80)
Muggia et al. 2000 (GOG 132) 	1992-1994 	Phase 3 (C) 	1. Cisplatin2. Paclitaxel 	Did not meet primary endpoint of PFS
Markman et al. 2001 (GOG 114) 	1992-1995 	Phase 3 (C) 	Carboplatin, then IP Cisplatin & IV Paclitaxel 	Might have shorter OS (primary endpoint)Median OS: 52 vs 63 mo(HR 1.23, 90% CI 1.00-1.54)
Ozols et al. 2003 (GOG 158) 	Not reported 	Phase 3 (C) 	Carboplatin & Paclitaxel 	Seems to have non-inferior RFS
Rose et al. 2004 (GOG 152) 	1994-2001 	Phase 3 (C) 	Cisplatin & Paclitaxel; with interval debulking 	Did not meet primary endpoint of OS
Armstrong et al. 2006 (GOG 172)	1998-2001 	Phase 3 (C) 	IP Cisplatin & Paclitaxel 	Seems to have shorter OS (co-primary endpoint)Median OS: 49.7 vs 65.6 mo(RR 1.33, 95% CI 1.03-1.72)
Spriggs et al. 2007 (GOG 162) 	Not reported 	Phase 3 (C) 	Cisplatin & Paclitaxel; prolonged-infusion paclitaxel	Did not meet primary endpoint of OS
Note: Some references specify to give the cisplatin after the paclitaxel (i.e., on day 2)
====Preceding treatment====
*GOG 111, 132, 152: Primary debulking surgery, with suboptimal debulking
*GOG 114, 158, 172: Primary debulking surgery, with optimal debulking
====Chemotherapy====
*Cisplatin (Platinol) 75 mg/m2 IV once on day 1 or 2
*Paclitaxel (Taxol) 135 mg/m2 IV continuous infusion over 24 hours, started on day 1
====Supportive therapy====
*(details vary depending on reference):
*Dexamethasone (Decadron) with one of the following options:
**20 mg PO twice on day 1, given 12 and 6 hours prior to chemotherapy
**20 mg IV once on day 1, given 30 minutes prior to paclitaxel
*Diphenhydramine (Benadryl) 50 mg IV once on day 1, given 30 minutes prior to paclitaxel
*Cimetidine (Tagamet) 300 mg IV once on day 1, given 30 minutes prior to paclitaxel
*"Hydration and antiemetic agents" once on day 1, given prior to cisplatin
21-day cycle for 6 cycles
===Regimen variant #2, 75/175===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Piccart et al. 2000 (OV10)	1994-04 to 1995-08 	Phase 3 (E-RT-switch-ic)	Cisplatin & Cyclophosphamide 	Longer PFS (primary endpoint)Median PFS: 15.5 vs 11.5 mo(HR not reported, p=0.0005)Longer OS (secondary endpoint)Median OS: 35.6 vs 25.8 mo(HR not reported, p=0.0016)
Neijt et al. 2000 	1994-1997 	Phase 3 (C) 	Carboplatin & Paclitaxel 	Did not meet primary endpoint of PFS
Mouratidou et al. 2007 	1998-2002 	Phase 3 (E-switch-ic) 	Cisplatin & Cyclophosphamide 	Did not meet primary endpoint of PFS
van der Burg et al. 2014 	1999-2006 	Phase 3 (C) 	Cisplatin & Paclitaxel; weekly paclitaxel	Did not meet primary endpoint of PFSMedian PFS: 16.4 vs 18.5 mo(HR not reported)
====Preceding treatment====
*OV10: Primary debulking surgery, with optimal or suboptimal debulking
*Neijt et al. 2000: Primary debulking surgery was recommended
====Chemotherapy====
*Cisplatin (Platinol) 75 mg/m2 IV once on day 1, given second
*Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1, given first
21-day cycle for 6 or more cycles
===Regimen variant #3, 75/185===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy	Comparative Toxicity
du Bois et al. 2003 (AGO-OVAR 3)	1995-1997 	Phase 3 (C)	Carboplatin & Paclitaxel	Non-inferior PFS 	Worse QoL
====Preceding treatment====
*Primary debulking surgery
====Chemotherapy====
*Cisplatin (Platinol) 75 mg/m2 (maximum dose of 165 mg) IV over 30 minutes once on day 1, given second
*Paclitaxel (Taxol) 185 mg/m2 (maximum dose of 400 mg) IV over 3 hours once on day 1, given first
21-day cycle for 6 or more cycles
===References===
# GOG 111: McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 4;334(1):1-6. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# GOG 132: Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2000 Jan;18(1):106-15. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# OV10: Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000 May 3;92(9):699-708. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B, van Houwelingen HC. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000 Sep;18(17):3084-92. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# GOG 114: Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Feb 15;19(4):1001-7. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# GOG 158: Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003 Sep 1;21(17):3194-200. Epub 2003 Jul 14. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# AGO-OVAR 3: du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J; Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# GOG 152: Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Moore DH, Small JM; Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004 Dec 9;351(24):2489-97. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00002568
# GOG 172: Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00003322
## Subgroup analysis: Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Jan;100(1):27-32. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
##HRQoL analysis: Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D; Gynecologic Oncology Group. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Feb;25(4):437-443. link to original article link to EuroPMC
# Mouratidou D, Gennatas C, Michalaki V, Papadimitriou A, Andreadis CH, Sykiotis C, Tsavaris N. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Anticancer Res. 2007 Jan-Feb;27(1B):681-5. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# GOG 162: Spriggs DR, Brady MF, Vaccarello L, Clarke-Pearson DL, Burger RA, Mannel R, Boggess JF, Lee RB, Hanly M. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007 Oct 1;25(28):4466-71. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT00002717
# van der Burg ME, Onstenk W, Boere IA, Look M, Ottevanger PB, de Gooyer D, Kerkhofs LG, Valster FA, Ruit JB, van Reisen AG, Goey SH, van der Torren AM, ten Bokkel Huinink D, Kok TC, Verweij J, van Doorn HC. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer. Eur J Cancer. 2014 Oct;50(15):2592-601. Epub 2014 Aug 2. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
=Intraperitoneal therapy, first-line=
==IP Carboplatin & Paclitaxel==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Nagao et al. 2023 (iPocc)	2010-05 to 2016-08 	Phase 2/3 (E-switch-ic)	IV Carboplatin & Paclitaxel	Seems to have longer PFS (primary endpoint)Median PFS: 23.5 vs 20.7 mo(HR 0.83, 95% CI 0.69-0.99)
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 6 IP once on day 1
*Paclitaxel (Taxol) 80 mg/m2 IV over 60 minutes once per day on days 1, 8, 15
21-day cycle for 6 cycles
===References===
#iPocc: Nagao S, Fujiwara K, Yamamoto K, Tanabe H, Okamoto A, Takehara K, Saito M, Fujiwara H, Tan DSP, Yamaguchi S, Adachi S, Kikuchi A, Hirasawa T, Yokoi T, Nagai T, Sato T, Kamiura S, Fujishita A, Loong W-W, Chan K, Syks P, Olawaye A, Ryu S-Y, Shigeta H, Kondo E, Yokoyama Y, Matsumoto T, Hasegawa K, Enomoto T. Intraperitoneal Carboplatin for Ovarian Cancer - A Phase 2/3 Trial. NEJM Evid. 2023;2(5). link to original article dosing details in supplement have been reviewed by our editors EuroPMC jRCTs031180141
==IP Cisplatin & Paclitaxel==
===Regimen variant #1, IV paclitaxel===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Markman et al. 2001 (GOG 114)	1992-1995 	Phase 3 (E-switch-ic)	See link 	See link
====Preceding treatment====
*First-line carboplatin; AUC 9 x 2
====Chemotherapy====
*Cisplatin (Platinol) 100 mg/m2 IP once on day 2
*Paclitaxel (Taxol) 135 mg/m2 IV continuous infusion over 24 hours, started on day 1
21-day cycle for 6 cycles
===Regimen variant #2, IV/IP paclitaxel===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Armstrong et al. 2006 (GOG 172)	1998-2001 	Phase 3 (E-switch-ic)	Cisplatin & Paclitaxel; IV	Seems to have longer OS (co-primary endpoint)Median OS: 65.6 vs 49.7 mo(RR 0.75, 95% CI 0.58-0.97)
====Chemotherapy====
*Cisplatin (Platinol) 100 mg/m2 IP rapid infusion once on day 2
**Walker et al. 2006 instructs that the patient be rolled onto 4 different positions every 15 minutes to evenly distribute cisplatin
*Paclitaxel (Taxol) 135 mg/m2 IV continuous infusion over 24 hours, started on day 1, then 60 mg/m2 IP rapid infusion once on day 8
====Supportive therapy====
*(Varies per reference)
*"Standard premedication" for paclitaxel
*"Hydration and antiemetic agents" prior to cisplatin
*Intraperitoneal doses of cisplatin and paclitaxel are reconstituted in 2 liters of warm normal saline before infusion
*Additional 1 liter normal saline to be infused immediately after intraperitoneal paclitaxel
*Supportive medications left to investigator discretion
21-day cycle for 6 cycles
===References===
# GOG 114: Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Feb 15;19(4):1001-7. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# GOG 172: Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00003322
## Subgroup analysis: Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Jan;100(1):27-32. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
##HRQoL analysis: Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D; Gynecologic Oncology Group. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Feb;25(4):437-443. link to original article link to EuroPMC
=Maintenance after first-line therapy=
==Altretamine monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence
Rothenberg et al. 2001 (SWOG-9326)	1993-1997 	Phase 2
====Chemotherapy====
*Altretamine (Hexalen) 260 mg/m2/day PO on days 1 to 14, split into 4 daily doses
28-day cycle for 6 cycles
===References===
# SWOG-9326: Rothenberg ML, Liu PY, Wilczynski S, Hannigan EV, Weiner SA, Weiss GR, Hunter VJ, Chapman JA, Tiersten A, Kohler PC, Alberts DS. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). Gynecol Oncol. 2001 Aug;82(2):317-22. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
## Update: Alberts DS, Jiang C, Liu PY, Wilczynski S, Markman M, Rothenberg ML. Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. Int J Gynecol Cancer. 2004 Mar-Apr;14(2):224-8. link to original article EuroPMC
==Bevacizumab monotherapy==
===Regimen variant #1, 16 cycles===
FDA-recommended dose
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Walker et al. 2019 (GOG-252) 	2009-2011 	Non-randomized part of phase 3 RCT	 	
Pfisterer et al. 2023 (BOOST)	2011-11-11 to 2013-08-06	Phase 3 (C) 	Bevacizumab x 30 mo	Did not meet primary endpoint of PFS
Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. The FDA-recommended duration of treatment is 22 cycles (including the 6 cycles of combination chemotherapy).
====Preceding treatment====
*BOOST: First-line CP & Bevacizumab x 6
*GOG-252: First-line CP & Bevacizumab x 6 versus IP Carboplatin, IV Paclitaxel & Bevacizumab x 6 versus IP Cisplatin & Paclitaxel, IV Paclitaxel & Bevacizumab x 6
====Targeted therapy====
*Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycle for up to 16 cycles
===Regimen variant #2, indefinite===
Study 	Dates of enrollment	Evidence
Chan et al. 2016 (GOG-0262)	2010-2012 	Non-randomized part of phase 3 RCT
Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.
====Preceding treatment====
*First-line CP & Bevacizumab x 6
====Targeted therapy====
*Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycles
===References===
# GOG-0262: Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016 Feb 25;374(8):738-48. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01167712
# GOG-252: Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, Fujiwara K, Alberts DS, Zheng W, Tewari KS, Cohn DE, Powell MA, Van Le L, Davidson SA, Gray HJ, Rose PG, Aghajanian C, Myers T, Alvarez Secord A, Rubin SC, Mannel RS. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2019 Jun 1;37(16):1380-1390. Epub 2019 Apr 19. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00951496
#BOOST: Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P, El-Balat A, Kurtz JE, Canzler U, Sehouli J, Heubner ML, Hartkopf AD, Baumann K, Hasenburg A, Hanker LC, Belau A, Schmalfeldt B, Denschlag D, Park-Simon TW, Selle F, Jackisch C, Burges A, Lueck HJ, Emons G, Meier W, Gropp-Meier M, Schroeder W, de Gregorio N, Hilpert F, Harter P. Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial. J Clin Oncol. 2023 Feb 1;41(4):893-902. Epub 2022 Nov 4. link to original article EuroPMC NCT01462890
==Niraparib monotherapy==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator	Comparative Efficacy
González-Martín et al. 2019 (PRIMAOV)	2016-2018 	Phase 3 (E-RT-esc)	Placebo 	Longer PFS1 (primary endpoint)Median PFS: 13.8 vs 8.2 mo(HR 0.66, 95% CI 0.56-0.79)
Li et al. 2023 (PRIMEOV) 	2018-06-29 to 2019-11-11	Phase 3 (E-esc) 	Placebo 	Longer PFS (primary endpoint)Median PFS: 24.8 vs 8.3 mo(HR 0.45, 95% CI 0.34-0.60)
1Reported efficacy for PRIMAOV is for the overall population and is based on the 2023 update.
Note: there are studies named PRIMA and PRIME in other cancer types, not to be confused with these.
====Preceding treatment====
*First-line platinum-containing chemotherapy; neither specific agents, combinations, nor doses are specified in the protocol.
====Targeted therapy====
*Niraparib (Zejula) by the following laboratory- and weight-based criteria:
**Less than 77 kg OR platelet count less than 150 x 109/L: 200 mg PO once per day on days 1 to 28
**77 kg or more AND platelet count 150 x 109/L or more: 300 mg PO once per day on days 1 to 28
28-day cycle for up to 39 cycles (3 years)
===References===
# PRIMAOV: González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2391-2402. Epub 2019 Sep 28. link to original article EuroPMC NCT02655016
##Q-TWiST analysis: Barretina-Ginesta MP, Monk BJ, Han S, Pothuri B, Auranen A, Chase DM, Lorusso D, Anderson C, Abadie-Lacourtoisie S, Cloven N, Braicu EI, Amit A, Redondo A, Shah R, Kebede N, Hawkes C, Gupta D, Woodward T, O'Malley DM, González-Martín A. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial. Ther Adv Med Oncol. 2022 Sep 22;14:17588359221126149. link to original article link to PMC article EuroPMC
##Update: González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer. 2023 Aug;189:112908. Epub 2023 May 3. link to original article EuroPMC
##HRQoL analysis: Pothuri B, Han S, Chase DM, Heitz F, Burger RA, Gaba L, Van Le L, Guerra E, Bender D, Korach J, Cloven N, Churruca C, Follana P, DiSilvestro P, Baurain JF, Jardon K, Pisano C, Peen U, Mäenpää J, Gupta D, Bacqué E, Li Y, Compton N, Antonova J, Monk BJ, González-Martín A. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial. Gynecol Oncol. 2024 May;184:168-177. Epub 2024 Feb 6. link to original article EuroPMC
##Update: Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, Pérez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, González-Martín A. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol. 2024 Nov;35(11):981-992. Epub 2024 Sep 14. link to original article EuroPMC
#PRIMEOV: Li N, Zhu J, Yin R, Wang J, Pan L, Kong B, Zheng H, Liu J, Wu X, Wang L, Huang Y, Wang K, Zou D, Zhao H, Wang C, Lu W, Lin A, Lou G, Li G, Qu P, Yang H, Zhang Y, Cai H, Pan Y, Hao M, Liu Z, Cui H, Yang Y, Yao S, Zhen X, Hang W, Hou J, Wang J, Wu L. Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023 Sep 1;9(9):1230-1237. link to original article link to PMC article dosing details in abstract have been reviewed by our editors EuroPMC NCT03709316
#AGO-OVAR 28: NCT05009082
==Paclitaxel monotherapy==
===Regimen variant #1, 135 mg/m2 q4wk===
Study 	Dates of enrollment	Evidence
Gordon et al. 2011 (B9E-US-S302)	2002-2006 	Non-randomized part of phase 3 RCT
====Preceding treatment====
*First-line Carboplatin & Gemcitabine x 6 versus Carboplatin & Paclitaxel x 6
====Chemotherapy====
*Paclitaxel (Taxol) 135 mg/m2 IV once on day 1
28-day cycle for up to 12 cycles
===Regimen variant #2, 175 mg/m2 q3wk x 3===
Study 	Dates of enrollment	Evidence
Micha et al. 2005	2002-07 to 2003-08 	Phase 2, fewer than 20 patients in this subgroup
====Preceding treatment====
*First-line Carboplatin, Gemcitabine, Paclitaxel x 6
====Chemotherapy====
*Paclitaxel (Taxol) 175 mg/m2 IV over 60 minutes once on day 1
21-day cycle for 3 cycles
===Regimen variant #3, 175 mg/m2 q3wk x 12===
Study 	Dates of enrollment	Evidence
Micha et al. 2005	2002-07 to 2003-08 	Phase 2, fewer than 20 patients in this subgroup
====Preceding treatment====
*First-line Carboplatin, Gemcitabine, Paclitaxel x 6
====Chemotherapy====
*Paclitaxel (Taxol) 175 mg/m2 IV over 60 minutes once on day 1
21-day cycle for 12 cycles
===Regimen variant #4, 175 mg/m2 q4wk x 3===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Markman et al. 2003 (GOG 178)	1997-2001 	Phase 3 (C)	Paclitaxel x 12	Shorter PFSMedian PFS: 21 vs 28 mo(HR 2.33, 99% CI 1.08-5.00)
====Chemotherapy====
*Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
28-day cycle for 3 cycles
===Regimen variant #5, 175 mg/m2 q4wk x 12===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Markman et al. 2003 (GOG 178)	1997-2001 	Phase 3 (E-esc)	Paclitaxel x 3	Longer PFS (primary endpoint)Median PFS: 28 vs 21 mo(HR 0.43, 99% CI 0.20-0.93)
2.31 (99% confidence interval, 1.08 to 4.94
====Chemotherapy====
*Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
28-day cycle for 12 cycles
===References===
# GOG 178: Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D; SWOG; Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003 Jul 1;21(13):2460-5. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00003120
## Update: Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, Alberts D. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol. 2009 Aug;114(2):195-8. Epub 2009 May 17. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC
# Micha JP, Goldstein BH, Mattison JA, Bader K, Graham C, Rettenmaier MA, Brown JV, Markman M. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer. Gynecol Oncol. 2005 Jan;96(1):132-5. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Retrospective: Abaid LN, Goldstein BH, Micha JP, Rettenmaier MA, Brown JV 3rd, Markman M. Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma. Oncology. 2010;78(5-6):389-93. Epub 2010 Aug 27. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# B9E-US-S302: Gordon AN, Teneriello M, Janicek MF, Hines J, Lim PC, Chen MD, Vaccarello L, Homesley HD, McMeekin S, Burkholder TL, Wang Y, Zhao L, Orlando M, Obasaju CK, Gill JF, Tai DF. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer. Gynecol Oncol. 2011 Dec;123(3):479-85. Epub 2011 Oct 5. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00191646
==Pazopanib monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Du Bois et al. 2014 (AGO-OVAR 16)	2009-06 to 2010-08 	Phase 3 (E-esc)	Placebo 	Longer PFS (primary endpoint)Median PFS: 17.9 vs 12.3 mo(HR 0.77, 95% CI 0.64-0.91)
Patients enrolled in AGO-OVAR 16 had histologically confirmed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, were FIGO II to IV, and no evidence of progression after initial treatment.
====Preceding treatment====
*Surgery and at least 5 cycles of first-line platinum and taxane combination chemotherapy
====Targeted therapy====
*Pazopanib (Votrient) 800 mg PO once per day
24-month course
===References===
# AGO-OVAR 16: du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014 Oct 20;32(30):3374-82. Epub 2014 Sep 15. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00866697
## Subgroup analysis: Kim JW, Mahner S, Wu LY, Shoji T, Kim BG, Zhu JQ, Takano T, Park SY, Kong BH, Wu Q, Wang KL, Ngan HY, Liu JH, Wei LH, Mitrica I, Zhang P, Crescenzo R, Wang Q, Cox CJ, Harter P, du Bois A. Pazopanib maintenance therapy in East Asian women with advanced epithelial ovarian cancer: results from AGO-OVAR16 and an East Asian Study. Int J Gynecol Cancer. 2018 Jan;28(1):2-10. link to original article EuroPMC
## Update: Vergote I, du Bois A, Floquet A, Rau J, Kim JW, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Colombo N, Mirza MR, Monk BJ, Tsibulak I, Calvert PM, Herzog TJ, Hanker LC, Meunier J, Lee JY, Bologna A, Carrasco-Alfonso MJ, Harter P. Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2019 Nov;155(2):186-191. Epub 2019 Sep 10. link to original article EuroPMC
==Rucaparib monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Monk et al. 2022 (ATHENA-MONO)	2018-2020 	Phase 3 (E-esc)	Placebo 	Longer PFS (primary endpoint)Median PFS: 20.2 vs 9.2 mo(HR 0.52, 95% CI 0.40-0.68)
====Preceding treatment====
*First-line platinum doublet chemotherapy
====Targeted therapy====
*Rucaparib (Rubraca) 600 mg PO twice per day on days 1 to 28
28-day cycles
===References===
# ATHENA-MONO: Monk BJ, Parkinson C, Lim MC, O'Malley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S, Christopoulou A, Provencher D, Prendergast E, Demirkiran F, Mikheeva O, Yeku O, Chudecka-Glaz A, Schenker M, Littell RD, Safra T, Chou HH, Morgan MA, Drochýtek V, Barlin JN, Van Gorp T, Ueland F, Lindahl G, Anderson C, Collins DC, Moore K, Marme F, Westin SN, McNeish IA, Shih D, Lin KK, Goble S, Hume S, Fujiwara K, Kristeleit RS. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022 Dec 1;40(34):3952-3964. Epub 2022 Jun 6. link to original article link to PMC article EuroPMC NCT03522246
=Second-line therapy for relapsed or recurrent disease, platinum-sensitive=
==Carboplatin monotherapy==
===Regimen variant #1, AUC 5===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Parmar et al. 2003 (ICON4) 	1996-2002 	Phase 3 (C)	1a. Carboplatin & Paclitaxel1b. Cisplatin & Paclitaxel	Seems to have shorter OSMedian OS: 24 vs 29 mo(HR 1.22, 95% CI 1.03-1.45)
Pfisterer et al. 2006 (AGO-OVAR 2.5)	1999-2002 	Phase 3 (C)	Carboplatin & Gemcitabine 	Shorter PFSMedian PFS: 5.8 vs 8.6 mo(HR 1.39, 95% CI 1.11-1.72)
Alberts et al. 2007 (SWOG S0200) 	2002-08 to 2004-12 	Phase 3 (C)	Carboplatin & PLD 	Did not meet primary endpoint of OS1
1Reported efficacy for SWOG S0200 is based on the 2009 update.
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 5 IV once on day 1
21-day cycle for 6 to 10 cycles
===Regimen variant #2, 300 mg/m2===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Bolis et al. 2001 (ARGO 96)	1991 to not reported	Phase 3 (C)	Carboplatin & Epirubicin	Did not meet primary endpoint of ORR
====Chemotherapy====
*Carboplatin (Paraplatin) 300 mg/m2 IV once on day 1
28-day cycle for 5 cycles
===References===
# ARGO 96: Bolis G, Scarfone G, Giardina G, Villa A, Mangili G, Melpignano M, Presti M, Tateo S, Franchi M, Parazzini F; Associazione per la Ricerca in Ginecologia Oncologia Study Group. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol. 2001 Apr;81(1):3-9. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# ICON4: Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON; AGO. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003 Jun 21;361(9375):2099-106. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00002894
# AGO-OVAR 2.5: Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E; AGO-OVAR; NCIC-CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC-CTG, and the EORTC GCG. J Clin Oncol. 2006 Oct 10;24(29):4699-707. Epub 2006 Sep 11. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00102414
#SWOG S0200: Alberts DS, Liu PY, Wilczynski SP, Clouser MC, Lopez AM, Michelin DP, Lanzotti VJ, Markman M; Southwest Oncology Group. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol. 2008 Jan;108(1):90-4. Epub 2007 Oct 18. link to original article link to PMC article EuroPMC NCT00043082
##Update: Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM Jr, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol. 2010 Mar;116(3):323-5. Epub 2009 Dec 30. link to original article link to PMC article EuroPMC
==Carboplatin & Docetaxel (DCb)==
===Regimen variant #1, AUC 2/35, 3 weeks out of 4===
Study 	Dates of enrollment	Evidence
Kushner et al. 2007	Not reported 	Phase 2
Note: BSA was capped at 2 m2.
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 2 IV over 30 minutes once per day on days 1, 8, 15, given second
*Docetaxel (Taxotere) 35 mg/m2 (maximum dose of 70 mg) IV over 60 minutes once per day on days 1, 8, 15, given first
====Supportive therapy====
*Dexamethasone (Decadron) 4 mg PO the evening before, the morning of, and evening after docetaxel
*5-HT3 antagonist once per day on days 1, 8, 15, prior to chemotherapy
*Phenothiazine or 5-HT3 antagonist as needed as an outpatient
*Diphenhydramine (Benadryl) 50 mg IV once per day on days 1, 8, 15, immediately prior to docetaxel
28-day cycle for 6 cycles
===Regimen variant #2, AUC 5/75===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Strauss et al. 2007 	2000-2003 	Phase 2 	 	
Vergote et al. 2016 (FAR-131)	2009 to not reported	Phase 3 (C) 	1a. CP & Farletuzumab; 1.25 mg/kg1b. DCb & Farletuzumab; 1.25 mg/kg2a. CP & Farletuzumab; 2.5 mg/kg2b. DCb & Farletuzumab; 2.5 mg/kg	Did not meet primary endpoint of PFS
Shi et al. 2021 (SOC-1) 	2012-2019 	Non-randomized part of phase 3 RCT	 	
Note: this was the lower bound of carboplatin dosing specified by FAR-131.
====Preceding treatment====
*SOC-1: Secondary cytoreduction versus no surgical intervention
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 5 IV over 30 to 60 minutes once on day 1, given second
*Docetaxel (Taxotere) 75 mg/m2 IV over 60 minutes once on day 1, given first
====Supportive therapy====
*Corticosteroids (route not specified) twice on day 1, given 12 hours and 30 minutes prior to docetaxel
*Prophylactic 5-HT3 antagonist
21-day cycle for varying durations: 6 cycles (FAR-131, Strauss et al. 2007); 6 to 9 cycles (SOC-1)
===Regimen variant #3, AUC 6/75===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Vergote et al. 2016 (FAR-131)	2009 to not reported	Phase 3 (C)	1a. CP & Farletuzumab; 1.25 mg/kg1b. DCb & Farletuzumab; 1.25 mg/kg2a. CP & Farletuzumab; 2.5 mg/kg2b. DCb & Farletuzumab; 2.5 mg/kg	Did not meet primary endpoint of PFS
Note: this was the upper bound of carboplatin dosing specified by FAR-131.
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 6 IV once on day 1
*Docetaxel (Taxotere) 75 mg/m2 IV once on day 1
21-day cycle for 6 cycles
===References===
# Strauss HG, Henze A, Teichmann A, Karbe I, Baumgart A, Thomssen C, Koelbl H. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. Gynecol Oncol. 2007 Mar;104(3):612-6. Epub 2006 Oct 27. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Kushner DM, Connor JP, Sanchez F, Volk M, Schink JC, Bailey HH, Harris LS, Stewart SL, Fine J, Hartenbach EM; Wisconsin Oncology Network. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol. 2007 May;105(2):358-64. Epub 2007 Jan 29. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# FAR-131: Vergote I, Armstrong D, Scambia G, Teneriello M, Sehouli J, Schweizer C, Weil SC, Bamias A, Fujiwara K, Ochiai K, Poole C, Gorbunova V, Wang W, O'Shannessy D, Herzog TJ. A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J Clin Oncol. 2016 Jul 1;34(19):2271-8. Epub 2016 Mar 21. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00849667
# SOC-1: Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, Jia H, Huang X, Cai Y, Yin S, Jiang R, Tian W, Gao W, Liu J, Yang H, Cheng X, Zang R. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Apr;22(4):439-449. Epub 2021 Mar 8. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT01611766
##Update: Jiang R, Feng Y, Chen Y, Cheng X, Shi T, Gao W, Jia H, Jiang S, Guo Y, Huang X, Tu D, Zhang Y, Yang H, Zhang P, Liu J, Zhu J, Zang R; SOC-1 Investigators. Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial. Nat Med. 2024 Aug;30(8):2181-2188. Epub 2024 Jun 1. link to original article EuroPMC
==Carboplatin & Pegylated liposomal doxorubicin==
CD: Carboplatin & Doxil (Pegylated liposomal doxorubicin)
PLDC: Pegylated Liposomal Doxorubicin & Carboplatin
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Pujade-Lauraine et al. 2010 (CALYPSO)	2005-2007 	Phase 3 (E-switch-ic) 	Carboplatin & Paclitaxel 	Longer PFS (primary endpoint)Median PFS: 11.3 vs 9.4 mo(HR 0.82, 95% CI 0.72-0.94)
Sehouli et al. 2016 (HECTOR) 	2007-2009 	Randomized Phase 2 (C)	Carboplatin & Topotecan 	Did not meet primary endpoint of PFS12
Colombo et al. 2023 (INOVATYON) 	2011-12 to 2017-09-18 	Phase 3 (C) 	PLD & Trabectedin 	Did not meet primary endpoint of OS
Pignata et al. 2021 (MITO 16) 	2013-2016 	Phase 3 (C) 	1a. Carboplatin, PLD, Bevacizumab1b. GCb & Bevacizumab1c. CP & Bevacizumab 	Shorter PFSMedian PFS: 8.8 vs 11.8 mo(HR 1.96, 95% CI 1.54-2.44)
Liu et al. 2022 (NRG-GY004) 	2016-02-04 to 2017-11-13	Phase 3 (C) 	1. Olaparib2. Cediranib & Olaparib 	Did not meet primary endpoint of PFS
González-Martín et al. 2024 (ANITA) 	2018-11-08 to 2022-01-24	Phase 3 (C) 	1a. Carboplatin, PLD, Atezolizumab1b. CP & Atezolizumab1c. GCb & Atezolizumab	Did not meet primary endpoint of PFSMedian PFS: 10.1 vs 11.2 mo(HR 1.12, 95% CI 0.91-1.41)
Note: CALYPSO stands for Caelyx (Pegylated liposomal doxorubicin) in Platinum Sensitive Ovarian patients
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 5 IV once on day 1
*Pegylated liposomal doxorubicin (Doxil) 30 mg/m2 IV once on day 1
====Supportive therapy====
*"Antiemetics, including a serotonin 5-HT3 antagonist and corticosteroid"
28-day cycle for varying durations: 4 or more cycles, depending on response and toxicity; 6 cycles (ANITA, MITO 16); 6 or more cycles (CALYPSO, INOVATYON); indefinitely (HECTOR, NRG-GY004)
====Subsequent treatment====
*ANITA: Niraparib maintenance
===References===
# CALYPSO: Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010 Jul 10;28(20):3323-9. Epub 2010 May 24. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00189553
## Update: Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, Gebski V, Pujade Lauraine E. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012 Aug 7;107(4):588-91. Epub 2012 Jul 26. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC
# HECTOR: Sehouli J, Chekerov R, Reinthaller A, Richter R, Gonzalez-Martin A, Harter P, Woopen H, Petru E, Hanker LC, Keil E, Wimberger P, Klare P, Kurzeder C, Hilpert F, Belau AK, Zeimet A, Bover-Barcelo I, Canzler U, Mahner S, Meier W; NOGGO; AGO; GEICO-ENGOT-GCIG. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). Ann Oncol. 2016 Dec;27(12):2236-2241. Epub 2016 Oct 26. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00437307
# MITO 16: Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, Bamias A, Salutari V, Selle F, Frezzini S, De Giorgi U, Pautier P, Bologna A, Orditura M, Dubot C, Gadducci A, Mammoliti S, Ray-Coquard I, Zafarana E, Breda E, Favier L, Ardizzoia A, Cinieri S, Largillier R, Sambataro D, Guardiola E, Lauria R, Pisano C, Raspagliesi F, Scambia G, Daniele G, Perrone F; MITO16b/MANGO–OV2/ENGOT–ov17 Investigators. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):267-276. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01802749
# NRG-GY004: Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, Cella D, Tew WP, Cloven NG, Muller CY, Bender DP, Moore RG, Michelin DP, Waggoner SE, Geller MA, Fujiwara K, D'Andre SD, Carney M, Alvarez Secord A, Moxley KM, Bookman MA. Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2022 Jul 1;40(19):2138-2147. Epub 2022 Mar 15. link to original article dosing details in supplement have been reviewed by our editors link to PMC article EuroPMC NCT02446600
#INOVATYON: Colombo N, Fossati R, Gadducci A, Bologna A, Sehouli J, Rulli E, Maenpaa J, Berger R, Sessa C, Montes A, Ottevanger NB, Vergote I, D'Incalci M, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Churruca Galaz C, Tasca G, Pardo B, Tognon G, Rubio-Perez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line. Br J Cancer. 2023 Apr;128(8):1503-1513. Epub 2023 Feb 9. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01379989
#ANITA: González-Martín A, Rubio MJ, Heitz F, Depont Christensen R, Colombo N, Van Gorp T, Romeo M, Ray-Coquard I, Gaba L, Leary A, De Sande LM, Lebreton C, Redondo A, Fabbro M, Barretina Ginesta MP, Follana P, Pérez-Fidalgo JA, Rodrigues M, Santaballa A, Sabatier R, Bermejo-Pérez MJ, Lotz JP, Pardo B, Marquina G, Sánchez-Lorenzo L, Quindós M, Estévez-García P, Guerra Alía E, Manso L, Casado V, Kommoss S, Tognon G, Henry S, Bruchim I, Oaknin A, Selle F. Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial. J Clin Oncol. 2024 Dec 20;42(36):4294-4304. Epub 2024 Sep 18. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT03598270
==Carboplatin, Pegylated liposomal doxorubicin, Bevacizumab==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Pfisterer et al. 2020 (AGO-OVAR 2.21/ENGOT-ov 18)	2013-2015 	Phase 3 (E-switch-ic)	GCb & Bevacizumab 	Seems to have longer PFS (primary endpoint)Median PFS: 13.3 vs 11.6 mo(HR 0.81, 95% CI 0.68-0.96)
Pignata et al. 2021 (MITO 16) 	2013-2016 	Phase 3 (E-esc) 	1a. Carboplatin & PLD1b. Carboplatin & Gemcitabine1c. CP 	Longer PFS (primary endpoint)Median PFS: 11.8 vs 8.8 mo(HR 0.51, 95% CI 0.41-0.65)
Kurtz et al. 2023 (ATALANTE) 	2016-09-28 to 2019-10-04	Phase 3 (C) 	1a. GCb, Atezolizumab, Bevacizumab1b. CP, Atezolizumab, Bevacizumab1c. Carboplatin, PLD, Atezolizumab, Bevacizumab	Might have shorter PFS (co-primary endpoint)Median PFS: 11.3 vs 13.5 mo(HR 1.20, 95% CI 1.01-1.45)
====Chemotherapy====
*Carboplatin (Paraplatin) as follows:
**Cycles 1 to 6: AUC 5 IV once on day 1
*Pegylated liposomal doxorubicin (Doxil) as follows:
**Cycles 1 to 6: 30 mg/m2 IV once on day 1
====Targeted therapy====
*Bevacizumab (Avastin) as follows:
**Cycles 1 to 6: 10 mg/kg IV once per day on days 1 & 15
**Cycle 7 onwards: 15 mg/kg IV once on day 1
28-day cycle for 6 cycles, then 21-day cycles
===References===
# AGO-OVAR 2.21/ENGOT-ov 18: Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2020 May;21(5):699-709. Epub 2020 Apr 16. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01837251
# MITO 16: Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, Bamias A, Salutari V, Selle F, Frezzini S, De Giorgi U, Pautier P, Bologna A, Orditura M, Dubot C, Gadducci A, Mammoliti S, Ray-Coquard I, Zafarana E, Breda E, Favier L, Ardizzoia A, Cinieri S, Largillier R, Sambataro D, Guardiola E, Lauria R, Pisano C, Raspagliesi F, Scambia G, Daniele G, Perrone F; MITO16b/MANGO–OV2/ENGOT–ov17 Investigators. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):267-276. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01802749
#ATALANTE: Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez García J, Petru E, Kocián R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier MA, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier É, Lebreton C, Lotz JP, Largillier R, Heudel PE, Heitz F; ATALANTE/ENGOT-ov29 Investigators. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. J Clin Oncol. 2023 Oct 20;41(30):4768-4778. Epub 2023 Aug 29. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT02891824
==Carboplatin & Gemcitabine (GCb)==
GCb: Gemcitabine & Carboplatin
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Pfisterer et al. 2006 (AGO-OVAR 2.5)	1999-2002 	Phase 3 (E-RT-esc) 	Carboplatin 	Longer PFS (primary endpoint)Median PFS: 8.6 vs 5.8 mo(HR 0.72, 95% CI 0.58-0.90)
Sehouli et al. 2016 (HECTOR) 	2007-2009 	Randomized Phase 2 (C) 	Carboplatin & Topotecan 	Did not meet primary endpoint of PFS12
Aghajanian et al. 2012 (OCEANS) 	2007-2010 	Phase 3 (C) 	GCb & Bevacizumab 	Shorter PFS (primary endpoint)Median PFS: 8.4 vs 12.4 mo(HR 2.08, 95% CI 1.64-2.56)Did not meet secondary endpoint of OS1Median OS: 32.9 vs 33.6 mo(HR 1.05, 95% CI 0.85-1.30)
Coleman et al. 2017 (NRG/GOG-0213) 	2007-2011 	Non-randomized part of phase 3 RCT	 	
Pignata et al. 2021 (MITO 16) 	2013-2016 	Phase 3 (C) 	1a. Carboplatin, PLD, Bevacizumab1b. GCb & Bevacizumab1c. CP & Bevacizumab 	Shorter PFSMedian PFS: 8.8 vs 11.8 mo(HR 1.96, 95% CI 1.54-2.44)
Liu et al. 2022 (NRG-GY004) 	2016-02-04 to 2017-11-13	Phase 3 (C) 	1. Olaparib2. Cediranib & Olaparib 	Did not meet primary endpoint of PFS
González-Martín et al. 2024 (ANITA) 	2018-11-08 to 2022-01-24	Phase 3 (C) 	1a. Carboplatin, PLD, Atezolizumab1b. CP & Atezolizumab1c. GCb & Atezolizumab	Did not meet primary endpoint of PFSMedian PFS: 10.1 vs 11.2 mo(HR 1.12, 95% CI 0.91-1.41)
1Reported efficacy for OCEANS is based on the 2015 update.
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 4 IV once on day 1
*Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on days 1 & 8
21-day cycle for varying durations: 6 cycles (ANITA, MITO 16, NRG/GOG-0213); 6 to 10 cycles (AGO-OVAR 2.5, OCEANS); indefinitely (HECTOR, NRG-GY004)
====Subsequent treatment====
*ANITA: Niraparib maintenance
===References===
# AGO-OVAR 2.5: Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E; AGO-OVAR; NCIC-CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC-CTG, and the EORTC GCG. J Clin Oncol. 2006 Oct 10;24(29):4699-707. Epub 2006 Sep 11. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00102414
# OCEANS: Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039-45. Epub 2012 Apr 23. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00434642
## Update: Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015 Oct;139(1):10-6. Epub 2015 Aug 10. link to original article link to PMC article EuroPMC
# HECTOR: Sehouli J, Chekerov R, Reinthaller A, Richter R, Gonzalez-Martin A, Harter P, Woopen H, Petru E, Hanker LC, Keil E, Wimberger P, Klare P, Kurzeder C, Hilpert F, Belau AK, Zeimet A, Bover-Barcelo I, Canzler U, Mahner S, Meier W; NOGGO; AGO; GEICO-ENGOT-GCIG. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). Ann Oncol. 2016 Dec;27(12):2236-2241. Epub 2016 Oct 26. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00437307
# NRG/GOG-0213: Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):779-791. Epub 2017 Apr 21. link to original article dosing details in abstract have been reviewed by our editors link to PMC article EuroPMC NCT00565851
## Update: Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019 Nov 14;381(20):1929-1939. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC
# MITO 16: Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, Bamias A, Salutari V, Selle F, Frezzini S, De Giorgi U, Pautier P, Bologna A, Orditura M, Dubot C, Gadducci A, Mammoliti S, Ray-Coquard I, Zafarana E, Breda E, Favier L, Ardizzoia A, Cinieri S, Largillier R, Sambataro D, Guardiola E, Lauria R, Pisano C, Raspagliesi F, Scambia G, Daniele G, Perrone F; MITO16b/MANGO–OV2/ENGOT–ov17 Investigators. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):267-276. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01802749
# NRG-GY004: Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, Cella D, Tew WP, Cloven NG, Muller CY, Bender DP, Moore RG, Michelin DP, Waggoner SE, Geller MA, Fujiwara K, D'Andre SD, Carney M, Alvarez Secord A, Moxley KM, Bookman MA. Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2022 Jul 1;40(19):2138-2147. Epub 2022 Mar 15. link to original article dosing details in supplement have been reviewed by our editors link to PMC article EuroPMC NCT02446600
#ANITA: González-Martín A, Rubio MJ, Heitz F, Depont Christensen R, Colombo N, Van Gorp T, Romeo M, Ray-Coquard I, Gaba L, Leary A, De Sande LM, Lebreton C, Redondo A, Fabbro M, Barretina Ginesta MP, Follana P, Pérez-Fidalgo JA, Rodrigues M, Santaballa A, Sabatier R, Bermejo-Pérez MJ, Lotz JP, Pardo B, Marquina G, Sánchez-Lorenzo L, Quindós M, Estévez-García P, Guerra Alía E, Manso L, Casado V, Kommoss S, Tognon G, Henry S, Bruchim I, Oaknin A, Selle F. Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial. J Clin Oncol. 2024 Dec 20;42(36):4294-4304. Epub 2024 Sep 18. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT03598270
==Carboplatin & Gemcitabine (GCb) & Bevacizumab==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Aghajanian et al. 2012 (OCEANS) 	2007-2010 	Phase 3 (E-RT-esc) 	GCb 	Longer PFS (primary endpoint)Median PFS: 12.4 vs 8.4 mo(HR 0.48, 95% CI 0.39-0.61)Did not meet secondary endpoint of OS1Median OS: 33.6 vs 32.9 mo(HR 0.95, 95% CI 0.77-1.18)
Coleman et al. 2017 (NRG/GOG-0213) 	2007-2011 	Non-randomized part of phase 3 RCT	 	
Pfisterer et al. 2020 (AGO-OVAR 2.21/ENGOT-ov 18)	2013-2015 	Phase 3 (C) 	Carboplatin, Doxil, Bevaciuzmab 	Seems to have shorter PFSMedian PFS: 11.6 vs 13.3 mo(HR 1.23, 95% CI 1.04-1.47)
Pignata et al. 2021 (MITO 16) 	2013-2016 	Phase 3 (E-esc) 	1a. Carboplatin & PLD1b. Carboplatin & Gemcitabine1c. CP 	Longer PFS (primary endpoint)Median PFS: 11.8 vs 8.8 mo(HR 0.51, 95% CI 0.41-0.65)
Kurtz et al. 2023 (ATALANTE) 	2016-09-28 to 2019-10-04	Phase 3 (C) 	1a. GCb, Atezolizumab, Bevacizumab1b. CP, Atezolizumab, Bevacizumab1c. Carboplatin, PLD, Atezolizumab, Bevacizumab	Might have shorter PFS (co-primary endpoint)Median PFS: 11.3 vs 13.5 mo(HR 1.20, 95% CI 1.01-1.45)
1Reported efficacy for OCEANS is based on the 2015 update.
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 4 IV once on day 1
*Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on days 1 & 8
====Targeted therapy====
*Bevacizumab (Avastin) 15 mg/kg IV once on day 1, given first
21-day cycle for varying durations: 6 cycles (AGO-OVAR 2.21/ENGOT-ov 18, ATALANTE, MITO 16); 6 to 8 cycles (NRG/GOG-0213); 6 to 10 cycles (OCEANS) 
====Subsequent treatment====
*Bevacizumab maintenance
===References===
# OCEANS: Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039-45. Epub 2012 Apr 23. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00434642
## Update: Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015 Oct;139(1):10-6. Epub 2015 Aug 10. link to original article link to PMC article EuroPMC
# NRG/GOG-0213: Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):779-791. Epub 2017 Apr 21. link to original article dosing details in abstract have been reviewed by our editors link to PMC article EuroPMC NCT00565851
## Update: Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019 Nov 14;381(20):1929-1939. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC
# AGO-OVAR 2.21/ENGOT-ov 18: Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2020 May;21(5):699-709. Epub 2020 Apr 16. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01837251
# MITO 16: Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, Bamias A, Salutari V, Selle F, Frezzini S, De Giorgi U, Pautier P, Bologna A, Orditura M, Dubot C, Gadducci A, Mammoliti S, Ray-Coquard I, Zafarana E, Breda E, Favier L, Ardizzoia A, Cinieri S, Largillier R, Sambataro D, Guardiola E, Lauria R, Pisano C, Raspagliesi F, Scambia G, Daniele G, Perrone F; MITO16b/MANGO–OV2/ENGOT–ov17 Investigators. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):267-276. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01802749
#ATALANTE: Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez García J, Petru E, Kocián R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier MA, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier É, Lebreton C, Lotz JP, Largillier R, Heudel PE, Heitz F; ATALANTE/ENGOT-ov29 Investigators. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. J Clin Oncol. 2023 Oct 20;41(30):4768-4778. Epub 2023 Aug 29. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT02891824
==Carboplatin & Paclitaxel (CP)==
CP: Carboplatin & Paclitaxel
PC: Paclitaxel & Carboplatin
===Regimen variant #1, AUC 5/175===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Parmar et al. 2003 (ICON4) 	1996-2002 	Phase 3 (E-esc) 	1a. Carboplatin1b. Cisplatin 	Seems to have longer OS (primary endpoint)Median OS: 29 vs 24 mo(HR 0.82, 95% CI 0.69-0.97)
Pujade-Lauraine et al. 2010 (CALYPSO)	2005-2007 	Phase 3 (C) 	Carboplatin & PLD 	Shorter PFSMedian PFS: 9.4 vs 11.3 mo(HR 1.22, 95% CI 1.06-1.39)
Sehouli et al. 2016 (HECTOR) 	2007-2009 	Randomized Phase 2 (C) 	Carboplatin & Topotecan 	Did not meet primary endpoint of PFS12
Coleman et al. 2017 (NRG/GOG-0213) 	2007-2011 	Phase 3 (C) 	CP & Bevacizumab 	Might have shorter OSMedian OS: 37.3 vs 42.2 mo(HR 1.20, 95% CI 0.995-1.47)
Vergote et al. 2019 (OAS 07OVA) 	2009-2013 	Phase 3 (C) 	Carboplatin & Paclitaxel micellar 	Non-inferior PFS
Pignata et al. 2017 (MITO-8) 	2009-2015 	Phase 3 (C) 	Investigator's choice1 of:1a. PLD1b. Topotecan1c. Gemcitabine 	Did not meet primary endpoint of OS
Vergote et al. 2016 (FAR-131) 	2009 to not reported 	Phase 3 (C) 	1a. CP & Farletuzumab; 1.25 mg/kg1b. DCb & Farletuzumab; 1.25 mg/kg2a. CP & Farletuzumab; 2.5 mg/kg2b. DCb & Farletuzumab; 2.5 mg/kg	Did not meet primary endpoint of PFS
Oza et al. 2014 (D0810C00041) 	2010-02-12 to 2010-07-30	Randomized Phase 2 (C) 	CP & Olaparib 	Shorter PFSMedian PFS: 9.6 vs 12.2 mo(HR 1.96, 95% CI 1.30-2.94)
Shi et al. 2021 (SOC-1) 	2012-2019 	Non-randomized part of phase 3 RCT	 	
Pignata et al. 2021 (MITO 16) 	2013-2016 	Phase 3 (C) 	1a. Carboplatin, PLD, Bevacizumab1b. GCb & Bevacizumab1c. CP & Bevacizumab 	Shorter PFSMedian PFS: 8.8 vs 11.8 mo(HR 1.96, 95% CI 1.54-2.44)
Liu et al. 2022 (NRG-GY004) 	2016-02-04 to 2017-11-13	Phase 3 (C) 	1. Olaparib2. Cediranib & Olaparib 	Did not meet primary endpoint of PFS
González-Martín et al. 2024 (ANITA) 	2018-11-08 to 2022-01-24	Phase 3 (C) 	1a. Carboplatin, PLD, Atezolizumab1b. CP & Atezolizumab1c. GCb & Atezolizumab 	Did not meet primary endpoint of PFSMedian PFS: 10.1 vs 11.2 mo(HR 1.12, 95% CI 0.91-1.41)
1Initially PLD was the only option. After an amendment in 2012, topotecan, gemcitabine, or "any other drug approved in this setting" were allowed.
====Preceding treatment====
*SOC-1: Secondary cytoreduction versus no surgical intervention
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 5 IV over 30 to 60 minutes once on day 1, given second
*Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1, given first
====Supportive therapy====
*(varies depending on reference):
*Corticosteroids and prophylactic 5-HT3 antagonist
*Premedication (with steroids & antihistamines) prior to paclitaxel
21-day cycle for varying durations: 6 cycles (ANITA, D0810C00041, FAR-131, MITO 16, OAS 07OVA); 6 to 8 cycles (NRG/GOG-0213); 6 to 9 cycles (MITO-8, SOC-1); indefinitely (CALYPSO, HECTOR, ICON4, NRG-GY004)
====Subsequent treatment====
*MITO-8, upon progression: Third-line non-platinum-based chemotherapy (NPBC)
*ANITA: Niraparib maintenance
===Regimen variant #2, AUC 6/175===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Vergote et al. 2019 (OAS 07OVA)	2009-2013 	Phase 3 (C) 	Carboplatin & Paclitaxel micellar 	Non-inferior PFS
Vergote et al. 2016 (FAR-131) 	2009 to not reported 	Phase 3 (C) 	1a. CP & Farletuzumab; 1.25 mg/kg1b. DCb & Farletuzumab; 1.25 mg/kg2a. CP & Farletuzumab; 2.5 mg/kg2b. DCb & Farletuzumab; 2.5 mg/kg	Did not meet primary endpoint of PFS
Oza et al. 2014 (D0810C00041) 	2010-02-12 to 2010-07-30	Randomized Phase 2 (C)	CP & Olaparib 	Shorter PFSMedian PFS: 9.6 vs 12.2 mo(HR 1.96, 95% CI 1.30-2.94)
Liu et al. 2022 (NRG-GY004) 	2016-02-04 to 2017-11-13	Phase 3 (C) 	1. Olaparib2. Cediranib & Olaparib 	Did not meet primary endpoint of PFS
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 6 IV over 30 to 60 minutes once on day 1
*Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
====Supportive therapy====
*(varies depending on reference):
*Corticosteroids and prophylactic 5-HT3 antagonist
*Premedication (with steroids & antihistamines) prior to paclitaxel
21-day cycle for varying durations: 6 cycles (D0810C00041, FAR-131, OAS 07OVA); indefinitely (NRG-GY004)
===References===
# ICON4: Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON; AGO. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003 Jun 21;361(9375):2099-106. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00002894
# CALYPSO: Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010 Jul 10;28(20):3323-9. Epub 2010 May 24. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00189553
## Update: Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, Gebski V, Pujade Lauraine E. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012 Aug 7;107(4):588-91. Epub 2012 Jul 26. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC
# D0810C00041: Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015 Jan;16(1):87-97. Epub 2014 Dec 4. Erratum in: Lancet Oncol. 2015 Feb;16(2):e55. Lancet Oncol. 2015 Jan;16(1):e6. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01081951
# FAR-131: Vergote I, Armstrong D, Scambia G, Teneriello M, Sehouli J, Schweizer C, Weil SC, Bamias A, Fujiwara K, Ochiai K, Poole C, Gorbunova V, Wang W, O'Shannessy D, Herzog TJ. A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J Clin Oncol. 2016 Jul 1;34(19):2271-8. Epub 2016 Mar 21. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00849667
# HECTOR: Sehouli J, Chekerov R, Reinthaller A, Richter R, Gonzalez-Martin A, Harter P, Woopen H, Petru E, Hanker LC, Keil E, Wimberger P, Klare P, Kurzeder C, Hilpert F, Belau AK, Zeimet A, Bover-Barcelo I, Canzler U, Mahner S, Meier W; NOGGO; AGO; GEICO-ENGOT-GCIG. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). Ann Oncol. 2016 Dec;27(12):2236-2241. Epub 2016 Oct 26. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00437307
# NRG/GOG-0213: Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):779-791. Epub 2017 Apr 21. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00565851
# MITO-8: Pignata S, Scambia G, Bologna A, Signoriello S, Vergote IB, Wagner U, Lorusso D, Murgia V, Sorio R, Ferrandina G, Sacco C, Cormio G, Breda E, Cinieri S, Natale D, Mangili G, Pisano C, Cecere SC, Di Napoli M, Salutari V, Raspagliesi F, Arenare L, Bergamini A, Bryce J, Daniele G, Piccirillo MC, Gallo C, Perrone F. Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study. J Clin Oncol. 2017 Oct 10;35(29):3347-3353. Epub 2017 Aug 21. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00657878
# OAS 07OVA: Vergote I, Bergfeldt K, Franquet A, Lisyanskaya AS, Bjermo H, Heldring N, Buyse M, Brize A. A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel. Gynecol Oncol. 2020 Feb;156(2):293-300. Epub 2019 Dec 9. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT00989131
# MITO 16: Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, Bamias A, Salutari V, Selle F, Frezzini S, De Giorgi U, Pautier P, Bologna A, Orditura M, Dubot C, Gadducci A, Mammoliti S, Ray-Coquard I, Zafarana E, Breda E, Favier L, Ardizzoia A, Cinieri S, Largillier R, Sambataro D, Guardiola E, Lauria R, Pisano C, Raspagliesi F, Scambia G, Daniele G, Perrone F; MITO16b/MANGO–OV2/ENGOT–ov17 Investigators. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):267-276. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01802749
# SOC-1: Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, Jia H, Huang X, Cai Y, Yin S, Jiang R, Tian W, Gao W, Liu J, Yang H, Cheng X, Zang R. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Apr;22(4):439-449. Epub 2021 Mar 8. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01611766
##Update: Jiang R, Feng Y, Chen Y, Cheng X, Shi T, Gao W, Jia H, Jiang S, Guo Y, Huang X, Tu D, Zhang Y, Yang H, Zhang P, Liu J, Zhu J, Zang R; SOC-1 Investigators. Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial. Nat Med. 2024 Aug;30(8):2181-2188. Epub 2024 Jun 1. link to original article EuroPMC
# NRG-GY004: Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, Cella D, Tew WP, Cloven NG, Muller CY, Bender DP, Moore RG, Michelin DP, Waggoner SE, Geller MA, Fujiwara K, D'Andre SD, Carney M, Alvarez Secord A, Moxley KM, Bookman MA. Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2022 Jul 1;40(19):2138-2147. Epub 2022 Mar 15. link to original article dosing details in supplement have been reviewed by our editors link to PMC article EuroPMC NCT02446600
#ANITA: González-Martín A, Rubio MJ, Heitz F, Depont Christensen R, Colombo N, Van Gorp T, Romeo M, Ray-Coquard I, Gaba L, Leary A, De Sande LM, Lebreton C, Redondo A, Fabbro M, Barretina Ginesta MP, Follana P, Pérez-Fidalgo JA, Rodrigues M, Santaballa A, Sabatier R, Bermejo-Pérez MJ, Lotz JP, Pardo B, Marquina G, Sánchez-Lorenzo L, Quindós M, Estévez-García P, Guerra Alía E, Manso L, Casado V, Kommoss S, Tognon G, Henry S, Bruchim I, Oaknin A, Selle F. Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial. J Clin Oncol. 2024 Dec 20;42(36):4294-4304. Epub 2024 Sep 18. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT03598270
==Carboplatin & Paclitaxel (CP) & Bevacizumab==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Coleman et al. 2017 (NRG/GOG-0213)	2007-2011 	Phase 3 (E-RT-esc)	Carboplatin & Paclitaxel 	Might have longer OS (primary endpoint)Median OS: 42.2 vs 37.3 mo(HR 0.83, 95% CI 0.68-1.005)
Pignata et al. 2021 (MITO 16) 	2013-2016 	Phase 3 (E-esc) 	1a. Carboplatin & PLD1b. Carboplatin & Gemcitabine1c. CP 	Longer PFS (primary endpoint)Median PFS: 11.8 vs 8.8 mo(HR 0.51, 95% CI 0.41-0.65)
Kurtz et al. 2023 (ATALANTE) 	2016-09-28 to 2019-10-04	Phase 3 (C) 	1a. GCb, Atezolizumab, Bevacizumab1b. CP, Atezolizumab, Bevacizumab1c. Carboplatin, PLD, Atezolizumab, Bevacizumab	Might have shorter PFS (co-primary endpoint)Median PFS: 11.3 vs 13.5 mo(HR 1.20, 95% CI 1.01-1.45)
====Chemotherapy====
*Carboplatin (Paraplatin) as follows:
**Cycles 1 to 6 up to 8: AUC 5 IV over 60 minutes once on day 1, given third
*Paclitaxel (Taxol) as follows:
**Cycles 1 to 6 up to 8: 175 mg/m2 IV over 3 hours once on day 1, given first
====Targeted therapy====
*Bevacizumab (Avastin) 15 mg/kg IV over 90 minutes once on day 1, given second
**If tolerated, infusion time is reduced to 60 minutes with cycle 2, and 30 minutes with cycle 3 onwards
21-day cycles
===References===
# NRG/GOG-0213: Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):779-791. Epub 2017 Apr 21. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00565851
# MITO 16: Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, Bamias A, Salutari V, Selle F, Frezzini S, De Giorgi U, Pautier P, Bologna A, Orditura M, Dubot C, Gadducci A, Mammoliti S, Ray-Coquard I, Zafarana E, Breda E, Favier L, Ardizzoia A, Cinieri S, Largillier R, Sambataro D, Guardiola E, Lauria R, Pisano C, Raspagliesi F, Scambia G, Daniele G, Perrone F; MITO16b/MANGO–OV2/ENGOT–ov17 Investigators. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):267-276. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT01802749
#ATALANTE: Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez García J, Petru E, Kocián R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier MA, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier É, Lebreton C, Lotz JP, Largillier R, Heudel PE, Heitz F; ATALANTE/ENGOT-ov29 Investigators. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. J Clin Oncol. 2023 Oct 20;41(30):4768-4778. Epub 2023 Aug 29. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC
==Carboplatin & Paclitaxel (CP) & Olaparib==
CP & Olaparib: Carboplatin, Paclitaxel, Olaparib
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Oza et al. 2014 (D0810C00041)	2010-02-12 to 2010-07-30	Randomized Phase 2 (E-esc)	Carboplatin & Paclitaxel	Longer PFS (primary endpoint)Median PFS: 12.2 vs 9.6 mo(HR 0.51, 95% CI 0.34-0.77)
====Chemotherapy====
*Carboplatin (Paraplatin) as follows:
**Cycles 1 to 6: AUC 4 IV once on day 1
*Paclitaxel (Taxol) as follows:
**Cycles 1 to 6: 175 mg/m2 IV once on day 1
====Targeted therapy====
*Olaparib (Lynparza) as follows:
**Cycles 1 to 6: 200 mg PO twice per day on days 1 to 10
**Cycle 7 onwards: 400 mg PO twice per day on days 1 to 21
21-day cycles
===References===
# D0810C00041: Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015 Jan;16(1):87-97. Epub 2014 Dec 4. Erratum in: Lancet Oncol. 2015 Feb;16(2):e55. Lancet Oncol. 2015 Jan;16(1):e6. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01081951
==Cisplatin & Gemcitabine (GC)==
===Regimen===
Study 	Dates of enrollment	Evidence
Rose et al. 2003c	Not reported 	Phase 2
====Chemotherapy====
*Cisplatin (Platinol) 30 mg/m2 IV once per day on days 1 & 8, given second
*Gemcitabine (Gemzar) 750 mg/m2 IV over 30 minutes once per day on days 1 & 8, given first
====Supportive therapy====
*5-HT3 antagonists
*Corticosteroids
*Prochlorperazine (Compazine)
*Magnesium supplementation with cisplatin
21-day cycles
===References===
# Rose PG, Mossbruger K, Fusco N, Smrekar M, Eaton S, Rodriguez M. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol. 2003 Jan;88(1):17-21. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Cisplatin & Paclitaxel (TP)==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Parmar et al. 2003 (ICON4)	1996-2002 	Phase 3 (E-esc)	1a. Carboplatin1b. Cisplatin	Seems to have longer OS (primary endpoint)Median OS: 29 vs 24 mo(HR 0.82, 95% CI 0.69-0.97)
====Chemotherapy====
*Cisplatin (Platinol) 50 mg/m2 IV once on day 1
*Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
21-day cycles
===References===
# ICON4: Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON; AGO. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003 Jun 21;361(9375):2099-106. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00002894
==Etoposide monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence	Efficacy
Rose et al. 1998	1992-1995 	Phase 2 	ORR: 34%
====Chemotherapy====
*Etoposide (Vepesid) by the following exposure-based criteria:
**No prior pelvic radiation: 50 mg/m2 PO once per day on days 1 to 21
**Previous pelvic radiation: 30 mg/m2 PO once per day on days 1 to 21
28-day cycles
====Dose and schedule modifications====
*In patients with previous pelvic radiation, etoposide dose could be increased up to 50 mg/m2 depending on toxicity
===References===
# Rose PG, Blessing JA, Mayer AR, Homesley HD; Gynecologic Oncology Group. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998 Feb;16(2):405-10. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==nab-Paclitaxel monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence
Teneriello et al. 2009	2005-2006 	Phase 2
====Chemotherapy====
*Paclitaxel, nanoparticle albumin-bound (Abraxane) 260 mg/m2 IV over 30 minutes once on day 1
21-day cycle for 6 to 8 cycles
===References===
# Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ, Boehm KA, Williams A, Asmar L. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol. 2009 Mar 20;27(9):1426-31. Epub 2009 Feb 17. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
#ROSELLA: NCT05257408
=Intraperitoneal therapy, second-line=
==Intraperitoneal hyperthermic cisplatin==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Classe et al. 2024 (CHIPOR)	2011-05-11 to 2021-05-14	Phase 3 (E-esc)	Cytoreductive surgery without HIPEC	Seems to have longer OS (primary endpoint)Median OS: 54.3 vs 45.8 mo(HR 0.73, 95% CI 0.56-0.96)
====Preceding treatment====
*Platinum-based chemotherapy, with optional bevacizumab x 6
====Local therapy====
*Cytoreductive surgery
====Chemotherapy====
*Hyperthermic Cisplatin (Platinol) 75 mg/m2 IP over 60 minutes once, given during surgery
One treatment
===References===
# CHIPOR: Classe JM, Meeus P, Hudry D, Wernert R, Quenet F, Marchal F, Houvenaeghel G, Bats AS, Lecuru F, Ferron G, Brigand C, Berton D, Gladieff L, Joly F, Ray-Coquard I, Durand-Fontanier S, Liberale G, Pocard M, Georgeac C, Gouy S, Guilloit JM, Guyon F, Costan C, Rousselet JM, de Guerké L, Bakrin N, Brument E, Martin E, Asselain B, Campion L, Glehen O; UNICANCER/CHIPOR Investigators. Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial. Lancet Oncol. 2024 Dec;25(12):1551-1562. Epub 2024 Nov 14. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01376752
=Relapsed or recurrent disease, platinum-resistant=
==Altretamine monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence
Markman et al. 1998	Not reported 	Phase 2
Note: there is not enough information in the FDA label to determine for sure whether this is one of the registration trials; it is representative of many phase 2 trials of this agent.
====Chemotherapy====
*Altretamine (Hexalen) 260 mg/m2 PO once per day on days 1 to 14
28-day cycles
===References===
# Markman M, Blessing JA, Moore D, Ball H, Lentz SS; Gynecologic Oncology Group. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 1998 Jun;69(3):226-9. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Bevacizumab monotherapy==
AIM pathway regimen 2022-08-01
===Regimen===
Study 	Dates of enrollment	Evidence
Burger et al. 2007 	2002-2004 	Phase 2
Cannistra et al. 2007	2005 	Phase 2
====Targeted therapy====
*Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycles
===References===
# Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI; Gynecologic Oncology Group. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007 Nov 20;25(33):5165-71. Erratum in: J Clin Oncol. 2014 Nov 10;32(32):3686. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007 Nov 20;25(33):5180-6. Erratum in: J Clin Oncol. 2008 Apr 1;26(10):1773. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Docetaxel monotherapy==
AIM pathway regimen 2022-08-01
===Regimen===
Study 	Dates of enrollment	Evidence
Rose et al. 2003a	1998-06 to 2000-01 	Phase 2
====Chemotherapy====
*Docetaxel (Taxotere) 100 mg/m2 IV over 60 minutes once on day 1
====Supportive therapy====
*Dexamethasone (Decadron) 8 mg PO twice per day on days -1 to 2 (3 days)
*Diphenhydramine (Benadryl) 50 mg IV once on day 1, immediately prior to docetaxel
*Antiemetics as needed
21-day cycles
===References===
# Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, Moore DH; Gynecologic Oncology Group. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003 Feb;88(2):130-5. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Etoposide monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence	Efficacy
Rose et al. 1998	1992-1995 	Phase 2 	ORR: 27%
====Chemotherapy====
*Etoposide (Vepesid) by the following exposure-based criteria:
**No prior pelvic radiation: 50 mg/m2 PO once per day on days 1 to 21
**Previous pelvic radiation: 30 mg/m2 PO once per day on days 1 to 21
28-day cycles
====Dose and schedule modifications====
*In patients with previous pelvic radiation, etoposide dose could be increased up to 50 mg/m2 depending on toxicity
===References===
# Rose PG, Blessing JA, Mayer AR, Homesley HD; Gynecologic Oncology Group. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998 Feb;16(2):405-10. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Gemcitabine monotherapy==
===Regimen variant #1, 2 weeks out of 3===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Mutch et al. 2007 (B9E-US-S301)	2002-2004 	Phase 3 (E-switch-ic)	PLD 	Did not meet primary endpoint of PFSMedian PFS: 3.6 vs 3.1 mo(aHR 0.98, 95% CI 0.70-1.40)
Kurzeder et al. 2016 (PENELOPE)	2013-10-02 to 2014-09-18	Phase 3 (C) 	1a. Gemcitabine & Pertuzumab1b. Paclitaxel & Pertuzumab1c. Topotecan & Pertuzumab	Did not meet primary endpoint of PFSMedian PFS: 2.6 vs 4.3 mo(sHR 1.35, 95% CI 0.90-2.00)
====Chemotherapy====
*Gemcitabine (Gemzar) 1000 mg/m2 IV over 30 to 60 minutes once per day on days 1 & 8
21-day cycles
===Regimen variant #2, 3 weeks out of 4===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Ferrandina et al. 2008 (MITO-3)	2003-2007 	Phase 3 (E-switch-ic)	PLD 	Might have higher ORR (secondary endpoint)
Lheureux et al. 2021 (PHL-093) 	2014-2018 	Phase 3 (C) 	Adavosertib & Gemcitabine	Shorter PFS (primary endpoint)Median PFS: 3 vs 4.6 mo(HR 1.82, 95% CI 1.11-2.86)
Hamanishi et al. 2021 (NINJA) 	2015-10-07 to 2017-12-21	Phase 3 (C) 	Nivolumab 	Did not meet primary endpoint of OSMedian OS: 12.1 vs 10.1 mo(HR 1.00, 95% CI 0.77-1.25)
Awaiting publication (NItCHE) 	2020-ongoing 	Phase 3 (C) 	Niraparib & Dostarlimab 	TBD if different primary endpoint of OS
====Chemotherapy====
*Gemcitabine (Gemzar) 1000 mg/m2 IV over 30 minutes once per day on days 1, 8, 15
28-day cycles
===References===
# B9E-US-S301: Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR Jr, Marciniack M, Naumann RW, Secord AA. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007 Jul 1;25(19):2811-8. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00191607
# MITO-3: Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008 Feb 20;26(6):890-6. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# PENELOPE: Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Ottevanger P, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, Del Campo JM, Mahner S, Bastière-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A, Gonzalez-Martin A. Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-expressing platinum-resistant ovarian cancer (PENELOPE). J Clin Oncol. 2016 Jul 20;34(21):2516-25. Epub 2016 Jun 6. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01684878
## Update: Lorusso D, Hilpert F, González Martin A, Rau J, Ottevanger P, Greimel E, Lück HJ, Selle F, Colombo N, Kroep JR, Mirza MR, Berger R, Pardo B, Grischke EM, Berton-Rigaud D, Martinez-Garcia J, Vergote I, Redondo A, Cardona A, Bastière-Truchot L, du Bois A, Kurzeder C; PENELOPE trial investigators. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2019 Sep;29(7):1141-1147. Epub 2019 Aug 15. link to original article EuroPMC
#PHL-093: Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G, Olawaiye AB, Ellard SL, Weberpals JI, Wahner Hendrickson AE, Fleming GF, Welch S, Dhani NC, Stockley T, Rath P, Karakasis K, Jones GN, Jenkins S, Rodriguez-Canales J, Tracy M, Tan Q, Bowering V, Udagani S, Wang L, Kunos CA, Chen E, Pugh TJ, Oza AM. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 Jan 23;397(10271):281-292. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT02101775
#NINJA: Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H, Sakuragi N, Watari H, Takahashi N, Kato H, Hasegawa K, Yonemori K, Mizuno M, Takehara K, Niikura H, Sawasaki T, Nakao S, Saito T, Enomoto T, Nagase S, Suzuki N, Matsumoto T, Kondo E, Sonoda K, Aihara S, Aoki Y, Okamoto A, Takano H, Kobayashi H, Kato H, Terai Y, Takazawa A, Takahashi Y, Namba Y, Aoki D, Fujiwara K, Sugiyama T, Konishi I. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). J Clin Oncol. 2021 Nov 20;39(33):3671-3681. Epub 2021 Sep 2. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC JapicCTI-153004
# NItCHE: NCT04679064
==Gemcitabine & Pegylated liposomal doxorubicin==
===Regimen===
Study 	Dates of enrollment	Evidence
Ferrandina et al. 2005	2000-12 to 2004-01 	Phase 2
====Chemotherapy====
*Gemcitabine (Gemzar) 1000 mg/m2 IV over 30 minutes once per day on days 1 & 8
*Pegylated liposomal doxorubicin (Doxil) 30 mg/m2 IV over 60 minutes once on day 1, given first
====Supportive therapy====
*Metoclopramide (Reglan) once per day on days 1 & 8, prior to chemotherapy
21-day cycles
===References===
# Ferrandina G, Paris I, Ludovisi M, D'Agostino G, Testa A, Lorusso D, Zanghi M, Pisconti S, Pezzella G, Adamo V, Breda E, Scambia G. Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol Oncol. 2005 Aug;98(2):267-73. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Mirvetuximab soravtansine monotherapy==
===Regimen===
FDA-recommended dose
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Moore et al. 2021 (FORWARD I) 	2017-01-24 to 2018-04-23 	Phase 3 (E-RT-switch-ooc)	Physician's choice of:1a. Paclitaxel1b. Pegylated liposomal doxorubicin1c. Topotecan	Did not meet primary endpoint of PFSMedian PFS: 4.1 vs 4.4 mo(HR 0.98, 95% CI 0.73-1.31)
Moore et al. 2023 (MIRASOL) 	2020-02-03 to not reported	Phase 3 (E-switch-ooc) 	Physician's choice of:1a. Paclitaxel1b. Pegylated liposomal doxorubicin1c. Topotecan	Longer OS (secondary endpoint)Median OS: 16.46 vs 12.75 mo(HR 0.67, 95% CI 0.50-0.89)Longer PFS (primary endpoint)RMPFS12: 6.13 vs 4.72 mo
Matulonis et al. 2023 (SORAYA)	2020-06 to 2021-05 	Non-randomized (RT) 	 	
====Biomarker eligibility criteria====
*High folate receptor-alpha expression
====Antibody-drug conjugate therapy====
*Mirvetuximab soravtansine (Elahere) 6 mg/kg (based on adjusted ideal body weight) IV once on day 1
21-day cycles
===References===
# FORWARD I: Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Konecny GE, Banerjee S, Murphy CG, Tanyi JL, Hirte H, Konner JA, Lim PC, Prasad-Hayes M, Monk BJ, Pautier P, Wang J, Berkenblit A, Vergote I, Birrer MJ. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021 Jun;32(6):757-765. Epub 2021 Mar 2. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT02631876
# SORAYA: Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Marin MR, Harter P, Murphy CG, Wang J, Noble E, Esteves B, Method M, Coleman RL. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. J Clin Oncol. 2023 May 1;41(13):2436-2445. Epub 2023 Jan 30. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT04296890
#MIRASOL: Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 Dec 7;389(23):2162-2174. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT04209855
==Paclitaxel monotherapy==
===Regimen variant #1, 80 mg/m2 3 out of 4 weeks===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Pignata et al. 2015 (MITO 11)	2010-2013 	Randomized Phase 2 (C)	Paclitaxel & Pazopanib 	Shorter PFSMedian PFS: 3.49 vs 6.35 mo(HR 2.38, 95% CI 1.45-4.00)
Moore et al. 2021 (FORWARD I)	2017-01-24 to 2018-04-23	Phase 3 (C) 	Mirvetuximab soravtansine	Did not meet primary endpoint of PFSMedian PFS: 4.4 vs 4.1 mo(HR 1.02, 95% CI 0.76-1.37)
Awaiting publication (NItCHE)	2020-ongoing 	Phase 3 (C) 	Niraparib & Dostarlimab 	TBD if different primary endpoint of OS
====Biomarker eligibility criteria====
*FORWARD I: High folate receptor-alpha expression
====Chemotherapy====
*Paclitaxel (Taxol) 80 mg/m2 IV once per day on days 1, 8, 15
28-day cycles
===Regimen variant #2, 80 mg/m2 weekly===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Markman et al. 2006 	Not reported 	Phase 2 	 	
Lindemann et al. 2017 (Ovaresist) 	2002-2007 	Phase 3 (C) 	Tamoxifen 	Longer PFS1 (secondary endpoint)Median PFS: 12.7 vs 8.3 weeks(HR 0.65, 95% CI 0.49-0.86)
Pujade-Lauraine et al. 2014 (AURELIA)	2009-2011 	Phase 3 (C) 	1a. Paclitaxel & Bevacizumab1b. PLD & Bevacizumab1c. Topotecan & Bevacizumab 	Shorter PFSMedian PFS: 3.4 vs 6.7 mo(HR 2.08, 95% CI 1.67-2.63)
Monk et al. 2014 (TRINOVA-1) 	2010-2012 	Phase 3 (C) 	Paclitaxel & Trebananib 	Shorter PFS (primary endpoint)Median PFS: 5.4 vs 7.2 mo(HR 1.52, 95% CI 1.30-1.75)
Kurzeder et al. 2016 (PENELOPE) 	2013-10-02 to 2014-09-18 	Phase 3 (C) 	1a. Gemcitabine & Pertuzumab1b. Paclitaxel & Pertuzumab1c. Topotecan & Pertuzumab	Did not meet primary endpoint of PFSMedian PFS: 2.6 vs 4.3 mo(sHR 1.35, 95% CI 0.90-2.00)
Lee et al. 2024 (NRG-GY005) 	2016-02-05 to 2020-10-02 	Phase 2/3 (C)	1. Olaparib2. Cediranib & Olaparib 	Did not meet co-primary endpoints of PFS/OS
Arend et al. 2023 (OVAL) 	2017-12 to 2022-03 	Phase 3 (C) 	Ofra-vec 	Did not meet co-primary endpoints of PFS/OS
Moore et al. 2023 (MIRASOL) 	2020-02-03 to not reported	Phase 3 (C) 	Mirvetuximab soravtansine 	Shorter OSMedian OS: 12.75 vs 16.46 mo(HR 1.49, 95% CI 1.12-2.00)Shorter PFSRMPFS12: 4.72 vs 6.13 mo
1Ovaresist met its primary endpoint of better HrQOL for the experimental (tamoxifen) arm but had shorter PFS (secondary endpoint) for the experimental arm, and this is the efficacy reported here.
Note: PENELOPE reported giving paclitaxel on days 1, 8, 15 of a 21-day cycle, which is identical to the schedule below.
====Biomarker eligibility criteria====
*MIRASOL: High folate receptor-alpha expression
====Chemotherapy====
*Paclitaxel (Taxol) 80 mg/m2 IV over 60 minutes once on day 1
====Supportive therapy====
*Dexamethasone (Decadron) 10 mg IV or PO once on day 1, given 30 to 60 minutes prior to paclitaxel
*Diphenhydramine (Benadryl) 25 to 50 mg IV once on day 1, given 30 to 60 minutes prior to paclitaxel
*H2 blocker once on day 1, given 30 to 60 minutes prior to paclitaxel
7-day cycles
===Regimen variant #3, 175 mg/m2, q3wk, 3-hour infusion===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Eisenhauer et al. 1994 	1991-07-23 to 1992-03-06	Phase 3 (E-RT-esc)	Paclitaxel; 135 mg/m2 	Did not meet primary endpoint of ORRSeems to have longer PFS (secondary endpoint)
Gore et al. 1995 	1992-1993 	Non-randomized 	 	
ten Bokkel Huinink et al. 1997 	Not reported 	Phase 3 (C) 	Topotecan 	Might have shorter TTP1 (co-primary endpoint)Median TTP: 14.7 vs 18.9 weeks(HR not reported, p=0.08)
Cantù et al. 1999 	1992-1995 	Phase 3 (E-de-esc)	CAP 	Seems to have shorter OS (primary endpoint)Median OS: 34.7 vs 25.8 mo(HR 0.58, 95% CI 0.34-0.98)
Buda et al. 2004 	1994-1999 	Phase 3 (C) 	Epirubicin & Paclitaxel	Did not meet primary endpoint of OS
Awaiting publication (DOXIL-CAN-301)	1997-2000 	Phase 3 (C) 	PLD 	Not available2
1Reported efficacy for ten Bokkel Huinink et al. 1997 is based on the 2004 update.
2DOXIL-CAN-301 appears to have been published in abstract form only, in 2002; this abstract is no longer available.
====Chemotherapy====
*Paclitaxel (Taxol) 175 mg/m2 IV over 3 hours once on day 1
21-day cycles
===Regimen variant #4, 175 mg/m2, q3wk, 24-hour infusion===
Historic variant
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Omura et al. 2003	1992-1995 	Phase 3 (C)	Paclitaxel; 250 mg/m2	Seems to have lower ORR
====Chemotherapy====
*Paclitaxel (Taxol) 175 mg/m2 IV continuous infusion over 24 hours, started on day 1
21-day cycles
===Regimen variant #5, 200 mg/m2, q3wk===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Rosenberg et al. 2002	1995-1998 	Phase 3 (C)	Paclitaxel; weekly 67 mg/m2	Did not meet primary endpoint of ORR
====Chemotherapy====
*Paclitaxel (Taxol) 200 mg/m2 IV over 3 hours once on day 1
21-day cycles
===Regimen variant #6, with range===
Historic variant
Study 	Dates of enrollment 	Evidence
McGuire et al. 1989	Not reported 	Phase 2
Kohn et al. 1994 	1991-01-01 to 1992-04-01	Phase 2
====Chemotherapy====
*Paclitaxel (Taxol) with varying doses
===References===
# McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989 Aug 15;111(4):273-9. link to original article EuroPMC
# Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B, Canetta R. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994 Dec;12(12):2654-66. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M, Adamo DO, Davis P, Ognibene FP, Cunnion RE, Reed E. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst. 1994 Jan 5;86(1):18-24. link to original article EuroPMC
# Gore ME, Levy V, Rustin G, Perren T, Calvert AH, Earl H, Thompson JM. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer. 1995 Oct;72(4):1016-9. link to original article link to PMC article EuroPMC
# ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmström H, Coleman R, Fields SC, Heron JF. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997 Jun;15(6):2183-93. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
## Update: ten Bokkel Huinink W, Lane SR, Ross GA; International Topotecan Study Group. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol. 2004 Jan;15(1):100-3. link to original article EuroPMC
# Cantù MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, Dell'Anna T, Torri V, Colombo N. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol. 2002 Mar 1;20(5):1232-7. link to original article EuroPMC
# Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe B, Puistola U, Parö G. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol. 2002;41(5):418-24. link to original article EuroPMC
# Omura GA, Brady MF, Look KY, Averette HE, Delmore JE, Long HJ, Wadler S, Spiegel G, Arbuck SG. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol. 2003 Aug 1;21(15):2843-8. Epub 2003 Jun 13. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# Buda A, Floriani I, Rossi R, Colombo N, Torri V, Conte PF, Fossati R, Ravaioli A, Mangioni C; GONO. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, GONO (Gruppo Oncologico Nord Ovest) group and IOR (Istituto Oncologico Romagnolo) group. Br J Cancer. 2004 Jun 1;90(11):2112-7. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC
# Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, Waggoner S; Gynecologic Oncology Group. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Jun;101(3):436-40. Epub 2005 Dec 2. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# AURELIA: Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. Epub 2014 Mar 17. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00976911
## PRO analysis: Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. Epub 2014 Mar 31. link to original article link to PMC article EuroPMC
## Subgroup analysis: Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. link to original article EuroPMC
# TRINOVA-1: Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014 Jul;15(8):799-808. Epub 2014 Jun 17. link to original article EuroPMC NCT01204749
## Update: Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma H, Vogl FD, Bach BA, Oza AM. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol. 2016 Oct;143(1):27-34. Epub 2016 Aug 18. link to original article EuroPMC
# MITO 11: Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, Mosconi AM, Orditura M, Brandes AA, Arcangeli V, Panici PB, Pisano C, Cecere SC, Di Napoli M, Raspagliesi F, Maltese G, Salutari V, Ricci C, Daniele G, Piccirillo MC, Di Maio M, Gallo C, Perrone F; MITO. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015 May;16(5):561-8. Epub 2015 Apr 14. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01644825
# PENELOPE: Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Ottevanger P, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, Del Campo JM, Mahner S, Bastière-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A, Gonzalez-Martin A. Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-expressing platinum-resistant ovarian cancer (PENELOPE). J Clin Oncol. 2016 Jul 20;34(21):2516-25. Epub 2016 Jun 6. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01684878
## Update: Lorusso D, Hilpert F, González Martin A, Rau J, Ottevanger P, Greimel E, Lück HJ, Selle F, Colombo N, Kroep JR, Mirza MR, Berger R, Pardo B, Grischke EM, Berton-Rigaud D, Martinez-Garcia J, Vergote I, Redondo A, Cardona A, Bastière-Truchot L, du Bois A, Kurzeder C; PENELOPE trial investigators. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2019 Sep;29(7):1141-1147. Epub 2019 Aug 15. link to original article EuroPMC
# Ovaresist: Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). Br J Cancer. 2017 Feb 14;116(4):455-463. Epub 2017 Jan 24. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT02728622
# FORWARD I: Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Konecny GE, Banerjee S, Murphy CG, Tanyi JL, Hirte H, Konner JA, Lim PC, Prasad-Hayes M, Monk BJ, Pautier P, Wang J, Berkenblit A, Vergote I, Birrer MJ. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021 Jun;32(6):757-765. Epub 2021 Mar 2. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT02631876
# OVAL: Arend RC, Monk BJ, Shapira-Frommer R, Haggerty AF, Alvarez EA, Amit A, Alvarez Secord A, Muller C, Casado Herraez A, Herzog TJ, Tewari KS, Cohen JG, Huang M, Yachnin A, Holeman LL, Ledermann JA, Rachmilewitz Minei T, Buyse M, Fain Shmueli S, Lavi M, Harats D, Penson RT; OVAL/GOG-3018 Investigators. Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018). J Clin Oncol. 2024 Jan 10;42(2):170-179. Epub 2023 Oct 31. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT03398655
#MIRASOL: Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 Dec 7;389(23):2162-2174. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT04209855
#NRG-GY005: Lee JM, Brady MF, Miller A, Moore RG, MacKay H, McNally L, Lea J, Street D, Lheureux S, McDonald ME, Duska LR, Cantuaria G, Kavecansky J, Leath CA 3rd, Powell M, Cadungog MG, Rose PG, Kim YM, Huang HQ, Provencher M, Wenzel LB, Bookman MA, Kohn EC, Secord AA. Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005. J Clin Oncol. 2024 Dec 20;42(36):4305-4316. Epub 2024 Oct 3. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT02502266
# AGO-OVAR 2.29: NCT03353831
# DOXIL-CAN-301: NCT00653952
# EPIK-O: NCT04729387
# GOG-3059: NCT04729608
# NItCHE: NCT04679064
==Paclitaxel & Bevacizumab==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Pujade-Lauraine et al. 2014 (AURELIA)	2009-2011 	Phase 3 (E-RT-esc)	1a. Paclitaxel1b. PLD1c. Topotecan	Longer PFS (primary endpoint)Median PFS: 6.7 vs 3.4 mo(HR 0.48, 95% CI 0.38-0.60)
====Chemotherapy====
*Paclitaxel (Taxol) 80 mg/m2 IV once per day on days 1, 8, 15, 22
====Targeted therapy====
*Bevacizumab (Avastin) 10 mg/kg IV once per day on days 1 & 15
28-day cycles
===References===
# AURELIA: Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. Epub 2014 Mar 17. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00976911
## PRO analysis: Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. Epub 2014 Mar 31. link to original article link to PMC article EuroPMC
## Subgroup analysis: Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. link to original article EuroPMC
# NItCHE: NCT04679064
==Paclitaxel & Pazopanib==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Pignata et al. 2015 (MITO 11)	2010-2013 	Randomized Phase 2 (E-esc)	Paclitaxel	Longer PFS (primary endpoint)Median PFS: 6.35 vs 3.49 mo(HR 0.42, 95% CI 0.25-0.69)
====Chemotherapy====
*Paclitaxel (Taxol) 80 mg/m2 IV once per day on days 1, 8, 15
====Targeted therapy====
*Pazopanib (Votrient) 800 mg PO once per day on days 1 to 28, taken at least 2 hours after or 1 hour before eating
28-day cycles
===References===
# MITO 11: Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, Mosconi AM, Orditura M, Brandes AA, Arcangeli V, Panici PB, Pisano C, Cecere SC, Di Napoli M, Raspagliesi F, Maltese G, Salutari V, Ricci C, Daniele G, Piccirillo MC, Di Maio M, Gallo C, Perrone F; MITO. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015 May;16(5):561-8. Epub 2015 Apr 14. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01644825
==Pazopanib monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence
Friedlander et al. 2010	Not reported 	Phase 2
====Targeted therapy====
*Pazopanib (Votrient) 800 mg PO once per day on days 1 to 28
28-day cycles
===References===
# Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, Ma B, Hodge JP, Lager JJ. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010 Oct;119(1):32-7. Epub 2010 Jun 27. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Pegylated liposomal doxorubicin monotherapy==
===Regimen variant #1, 40 mg/m2===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Lindemann et al. 2017 (Ovaresist) 	2002-2007 	Phase 3 (C) 	Tamoxifen 	Longer PFS
Ferrandina et al. 2008 (MITO-3) 	2003-2007 	Phase 3 (E-switch-ic)	Gemcitabine 	Might have lower ORR (secondary endpoint)
Pujade-Lauraine et al. 2014 (AURELIA) 	2009-2011 	Phase 3 (C) 	1a. Paclitaxel & Bevacizumab1b. PLD & Bevacizumab1c. Topotecan & Bevacizumab	Shorter PFSMedian PFS: 3.4 vs 6.7 mo(HR 2.08, 95% CI 1.67-2.63)
Motohashi et al. 2020 (JGOG 3018) 	2010-2017 	Phase 3 (E-de-esc) 	PLD; 50 mg/m2 	Inconclusive whether non-inferior PFS (primary endpoint)
Pujade-Lauraine et al. 2021 (JAVELIN Ovarian 200)	2016-01-05 to 2017-05-16 	Phase 3 (C) 	1. Avelumab2. PLD & Avelumab 	Did not meet co-primary endpoints of PFS/OS
Lee et al. 2024 (NRG-GY005) 	2016-02-05 to 2020-10-02 	Phase 2/3 (C) 	1. Olaparib2. Cediranib & Olaparib 	Did not meet co-primary endpoints of PFS/OS
Moore et al. 2021 (FORWARD I) 	2017-01-24 to 2018-04-23 	Phase 3 (C) 	Mirvetuximab soravtansine 	Did not meet primary endpoint of PFSMedian PFS: 4.4 vs 4.1 mo(HR 1.02, 95% CI 0.76-1.37)
Moore et al. 2023 (MIRASOL) 	2020-02-03 to not reported	Phase 3 (C) 	Mirvetuximab soravtansine 	Shorter OSMedian OS: 12.75 vs 16.46 mo(HR 1.49, 95% CI 1.12-2.00)Shorter PFSRMPFS12: 4.72 vs 6.13 mo
Awaiting publication (NItCHE) 	2020-ongoing 	Phase 3 (C) 	Niraparib & Dostarlimab 	TBD if different primary endpoint of OS
Note: Ovaresist met its primary endpoint of better HrQOL for the experimental (tamoxifen) arm but had shorter PFS (secondary endpoint) for the experimental arm, and this is the efficacy reported here.
====Biomarker eligibility criteria====
*FORWARD I & MIRASOL: High folate receptor-alpha expression
====Chemotherapy====
*Pegylated liposomal doxorubicin (Doxil) 40 mg/m2 IV over 60 minutes once on day 1
====Supportive therapy====
*Methylprednisolone (Solumedrol) 20 mg IV once on day 1, given 30 minutes prior to pegylated liposomal doxorubicin
28-day cycles
===Regimen variant #2, 50 mg/m2===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Muggia et al. 1997 	1994-1995 	Phase 2 (RT) 	 	
Gordon et al. 2000 	Not reported to 1998 	Phase 2 (RT) 	 	
Gordon et al. 2001 (Doxil Study 30-49)	1997-1999 	Phase 3 (E-RT-switch-ic)	Topotecan 	Seems to have longer PFS (co-primary endpoint)Median PFS: 28.9 vs 23.3 weeks(HR not reported, p=0.037)
Mutch et al. 2007 (B9E-US-S301) 	2002-2004 	Phase 3 (C) 	Gemcitabine 	Did not meet primary endpoint of PFS
Vergote et al. 2009 (ASSIST-1) 	2003-2006 	Phase 3 (C) 	Canfosfamide 	Longer OS (primary endpoint)Median OS: 14.2 vs 8.5 mo
Awaiting publication (ASSIST-3) 	2004-2008 	Phase 3 (C) 	Canfosfamide & Carboplatin	Did not meet primary endpoint of PFS
Monk et al. 2010 (OVA-301) 	2005-2007 	Phase 3 (C) 	PLD & Trabectedin 	Seems to have shorter PFS (primary endpoint)Median PFS: 5.8 vs 7.3 mo(HR 1.27, 95% CI 1.04-1.54)Might have shorter OS1 (secondary endpoint)Median OS: 18.9 vs 22.2 mo(HR 1.16, 95% CI 0.98-1.39)
Colombo et al. 2012 (CEPO906A2303) 	2005-2009 	Phase 3 (C) 	Patupilone 	Did not meet primary endpoint of OS
Vergote et al. 2010 (ASSIST-5) 	2006-09 to 2007-06 	Phase 3 (C) 	Canfosfamide & PLD 	Did not meet primary endpoint of PFSMedian PFS: 3.7 vs 5.6 mo(HR 1.09)
Motohashi et al. 2020 (JGOG 3018) 	2010-2017 	Phase 3 (C) 	PLD; 40 mg/m2 	Inconclusive whether non-inferior PFS
Marth et al. 2016 (TRINOVA-2) 	2011-2013 	Phase 3 (C) 	PLD & Trebananib 	Did not meet primary endpoint of PFSMedian PFS: 7.2 vs 7.6 mo(HR 1.09, 95% CI 0.81-1.47)
Monk et al. 2020 (CR100983) 	2013-2018 	Phase 3 (C) 	PLD & Trabectedin 	Did not meet primary endpoint of OSMedian OS: 22.2 vs 23.8 mo(HR 1.09, 95% CI 0.85-1.37)
Gaillard et al. 2021 (CORAIL) 	2015-06-26 to 2018-10-12	Phase 3 (C) 	Lurbinectedin 	Did not meet primary endpoint of PFSMedian PFS: 3.6 vs 3.5 mo(HR 0.95)
Hamanishi et al. 2021 (NINJA) 	2015-10-07 to 2017-12-21	Phase 3 (C) 	Nivolumab 	Did not meet primary endpoint of OSMedian OS: 12.1 vs 10.1 mo(HR 1.00, 95% CI 0.77-1.25)
1Reported efficacy for OVA-301 is based on the 2012 update.
====Chemotherapy====
*Pegylated liposomal doxorubicin (Doxil) 50 mg/m2 IV over 60 to 90 minutes once on day 1
28-day cycles
===References===
# Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997 Mar;15(3):987-93. link to original article EuroPMC
# Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 2000 Sep;18(17):3093-100. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# Doxil Study 30-49: Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001 Jul 15;19(14):3312-22. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
## Update: Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004 Oct;95(1):1-8. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# B9E-US-S301: Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR Jr, Marciniack M, Naumann RW, Secord AA. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007 Jul 1;25(19):2811-8. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC content property of HemOnc.org NCT00191607
# MITO-3: Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008 Feb 20;26(6):890-6. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# ASSIST-1: Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, Kavanagh J, Vermorken JB, Meng L, Jones M, Brown G, Kaye S; ASSIST-1 Study Group. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer. 2009 Sep;45(13):2324-32. Epub 2009 Jun 8. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT00057720
# ASSIST-5: Vergote I, Finkler NJ, Hall JB, Melnyk O, Edwards RP, Jones M, Keck JG, Meng L, Brown GL, Rankin EM, Burke JJ, Boccia RV, Runowicz CD, Rose PG. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2010 Jul;20(5):772-80. link to original article EuroPMC NCT00350948
# OVA-301: Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010 Jul 1;28(19):3107-14. Epub 2010 Jun 1. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00113607
##PRO analysis: Krasner CN, Poveda A, Herzog TJ, Vermorken JB, Kaye SB, Nieto A, Claret PL, Park YC, Parekh T, Monk BJ. Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. Gynecol Oncol. 2012 Oct;127(1):161-7. Epub 2012 Jul 2. link to original article EuroPMC
## Update: Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer. 2012 Oct;48(15):2361-8. Epub 2012 Apr 26. link to original article EuroPMC
# CEPO906A2303: Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J, Souami F, Wing P, Engelholm S, Bamias A, Schwartz P. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol. 2012 Nov 1;30(31):3841-7. Epub 2012 Sep 17. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT00262990
# AURELIA: Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. Epub 2014 Mar 17. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00976911
## PRO analysis: Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. Epub 2014 Mar 31. link to original article link to PMC article EuroPMC
## Subgroup analysis: Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. link to original article EuroPMC
# TRINOVA-2: Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Altintas S, Rustin G, Wenham RM, Mirza MR, Fong PC, Oza A, Monk BJ, Ma H, Vogl FD, Bach BA. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur J Cancer. 2017 Jan;70:111-121. Epub 2016 Dec 1. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT01281254
# Ovaresist: Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). Br J Cancer. 2017 Feb 14;116(4):455-463. Epub 2017 Jan 24. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT02728622
# CR100983: Monk BJ, Herzog TJ, Wang G, Triantos S, Maul S, Knoblauch R, McGowan T, Shalaby WSW, Coleman RL. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer. Gynecol Oncol. 2020 Mar;156(3):535-544. Epub 2020 Jan 8. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT01846611
#JGOG 3018: Motohashi T, Yabuno A, Michimae H, Ohishi T, Nonaka M, Takano M, Nishio S, Fujiwara H, Fujiwara K, Kondo E, Sugiyama T, Tabata T. Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial. J Gynecol Oncol. 2021 Jan;32(1):e9. Epub 2020 Nov 10. link to original article dosing details in abstract have been reviewed by our editors link to PMC article EuroPMC UMIN000003130
# FORWARD I: Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Konecny GE, Banerjee S, Murphy CG, Tanyi JL, Hirte H, Konner JA, Lim PC, Prasad-Hayes M, Monk BJ, Pautier P, Wang J, Berkenblit A, Vergote I, Birrer MJ. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021 Jun;32(6):757-765. Epub 2021 Mar 2. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT02631876
# JAVELIN Ovarian 200: Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021 Jul;22(7):1034-1046. Epub 2021 Jun 15. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT02580058
#NINJA: Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H, Sakuragi N, Watari H, Takahashi N, Kato H, Hasegawa K, Yonemori K, Mizuno M, Takehara K, Niikura H, Sawasaki T, Nakao S, Saito T, Enomoto T, Nagase S, Suzuki N, Matsumoto T, Kondo E, Sonoda K, Aihara S, Aoki Y, Okamoto A, Takano H, Kobayashi H, Kato H, Terai Y, Takazawa A, Takahashi Y, Namba Y, Aoki D, Fujiwara K, Sugiyama T, Konishi I. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). J Clin Oncol. 2021 Nov 20;39(33):3671-3681. Epub 2021 Sep 2. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC JapicCTI-153004
#CORAIL: Gaillard S, Oaknin A, Ray-Coquard I, Vergote I, Scambia G, Colombo N, Fernandez C, Alfaro V, Kahatt C, Nieto A, Zeaiter A, Aracil M, Vidal L, Pardo-Burdalo B, Papai Z, Kristeleit R, O'Malley DM, Benjamin I, Pautier P, Lorusso D. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). Gynecol Oncol. 2021 Nov;163(2):237-245. Epub 2021 Sep 11. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT02421588
#MIRASOL: Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 Dec 7;389(23):2162-2174. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT04209855
#NRG-GY005: Lee JM, Brady MF, Miller A, Moore RG, MacKay H, McNally L, Lea J, Street D, Lheureux S, McDonald ME, Duska LR, Cantuaria G, Kavecansky J, Leath CA 3rd, Powell M, Cadungog MG, Rose PG, Kim YM, Huang HQ, Provencher M, Wenzel LB, Bookman MA, Kohn EC, Secord AA. Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005. J Clin Oncol. 2024 Dec 20;42(36):4305-4316. Epub 2024 Oct 3. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT02502266
# AGO-OVAR 2.29: NCT03353831
# ARTISTRY-7: NCT05092360
# ASSIST-3: NCT00102973
# EPIK-O: NCT04729387
# NItCHE: NCT04679064
# PROCEEDOV: NCT01170650
==Pegylated liposomal doxorubicin & Bevacizumab==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Pujade-Lauraine et al. 2014 (AURELIA)	2009-2011 	Phase 3 (E-RT-esc)	1a. Paclitaxel1b. PLD1c. Topotecan	Longer PFS (primary endpoint)Median PFS: 6.7 vs 3.4 mo(HR 0.48, 95% CI 0.38-0.60)
====Chemotherapy====
*Pegylated liposomal doxorubicin (Doxil) 40 mg/m2 IV once on day 1
====Targeted therapy====
*Bevacizumab (Avastin) 10 mg/kg IV once per day on days 1 & 15
28-day cycles
===References===
# AURELIA: Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. Epub 2014 Mar 17. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00976911
## PRO analysis: Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. Epub 2014 Mar 31. link to original article link to PMC article EuroPMC
## Subgroup analysis: Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. link to original article EuroPMC
# NItCHE: NCT04679064
==Pegylated liposomal doxorubicin & Trabectedin==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Monk et al. 2010 (OVA-301)	2005-2007 	Phase 3 (E-esc)	PLD 	Seems to have longer PFS (primary endpoint)Median PFS: 7.3 vs 5.8 mo(HR 0.79, 95% CI 0.65-0.96)Might have longer OS1 (secondary endpoint)Median OS: 22.2 vs 18.9 mo(HR 0.86, 95% CI 0.72-1.02)
1Reported efficacy is based on the 2012 update.
====Chemotherapy====
*Pegylated liposomal doxorubicin (Doxil) 30 mg/m2 IV over 90 minutes once on day 1, given first
*Trabectedin (Yondelis) 1.1 mg/m2 IV over 3 hours once on day 1, given second, 30 minutes later
21-day cycles
===References===
# OVA-301: Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010 Jul 1;28(19):3107-14. Epub 2010 Jun 1. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00113607
##PRO analysis: Krasner CN, Poveda A, Herzog TJ, Vermorken JB, Kaye SB, Nieto A, Claret PL, Park YC, Parekh T, Monk BJ. Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. Gynecol Oncol. 2012 Oct;127(1):161-7. Epub 2012 Jul 2. link to original article EuroPMC
## Update: Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer. 2012 Oct;48(15):2361-8. Epub 2012 Apr 26. link to original article EuroPMC
==Pemetrexed monotherapy==
===Regimen variant #1, 700 mg/m2===
Study 	Dates of enrollment	Evidence
Miller et al. 2009 (GOG-0126Q)	2004-2006 	Phase 2
Note: this was the dosage for patients with previous radiation therapy.
====Chemotherapy====
*Pemetrexed (Alimta) 700 mg/m2 IV over 10 minutes once on day 1
====Supportive therapy====
*Folic acid 350 to 600 mcg PO once per day, starting 7 days prior to pemetrexed, to continue throughout therapy
*Cyanocobalamin (Vitamin B12) 1000 mcg IM once, 7 days prior to pemetrexed, then 1000 mcg IM once every 9 weeks
*Dexamethasone (Decadron) 4 mg PO twice per day the day before, the day of, and day after pemetrexed
*No NSAIDs (nonsteroidal anti-inflammatory drugs) for 2 days before or after pemetrexed 
21-day cycles
===Regimen variant #2, 900 mg/m2===
Study 	Dates of enrollment	Evidence
Miller et al. 2009 (GOG-0126Q)	2004-2006 	Phase 2
====Chemotherapy====
*Pemetrexed (Alimta) 900 mg/m2 IV over 10 minutes once on day 1
====Supportive therapy====
*Folic acid 350 to 600 mcg PO once per day, starting 7 days prior to pemetrexed, to continue throughout therapy
*Cyanocobalamin (Vitamin B12) 1000 mcg IM once, 7 days prior to pemetrexed, then 1000 mcg IM once every 9 weeks
*Dexamethasone (Decadron) 4 mg PO twice per day the day before, the day of, and day after pemetrexed
*No NSAIDs (nonsteroidal anti-inflammatory drugs) for 2 days before or after pemetrexed 
21-day cycles
===References===
# GOG-0126Q: Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH; Gynecologic Oncology Group. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009 Jun 1;27(16):2686-91. Epub 2009 Mar 30. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00087087
==Topotecan monotherapy==
===Regimen variant #1, 4 mg/m2, 3 weeks out of 4===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Sehouli et al. 2010 (TOWERov) 	2005-2008 	Randomized Phase 2 (E-switch-ic)	Topotecan; q3wk 	Did not meet primary endpoint of CBR
Pujade-Lauraine et al. 2014 (AURELIA)	2009-2011 	Phase 3 (C) 	1a. Paclitaxel & Bevacizumab1b. PLD & Bevacizumab1c. Topotecan & Bevacizumab	Shorter PFSMedian PFS: 3.4 vs 6.7 mo(HR 2.08, 95% CI 1.67-2.63)
Lee et al. 2024 (NRG-GY005) 	2016-02-05 to 2020-10-02 	Phase 2/3 (C) 	1. Olaparib2. Cediranib & Olaparib 	Did not meet co-primary endpoints of PFS/OS
Moore et al. 2021 (FORWARD I) 	2017-01-24 to 2018-04-23 	Phase 3 (C) 	Mirvetuximab soravtansine 	Did not meet primary endpoint of PFSMedian PFS: 4.4 vs 4.1 mo(HR 1.02, 95% CI 0.76-1.37)
Moore et al. 2023 (MIRASOL) 	2020-02-03 to not reported	Phase 3 (C) 	Mirvetuximab soravtansine 	Shorter OSMedian OS: 12.75 vs 16.46 mo(HR 1.49, 95% CI 1.12-2.00)Shorter PFSRMPFS12: 4.72 vs 6.13 mo
Note: TOWER should not be confused with the trial by the same name in B-ALL.
====Biomarker eligibility criteria====
*FORWARD I & MIRASOL: High folate receptor-alpha expression
====Chemotherapy====
*Topotecan (Hycamtin) 4 mg/m2 IV over 30 minutes once per day on days 1, 8, 15
28-day cycle for varying durations: 13 cycles (TOWERov); indefinitely (all others)
===Regimen variant #2, 6.25 mg/m2, split dosing, q3wk===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Sehouli et al. 2008 	1999-2004 	Phase 3 (C) 	1. Etoposide & Topotecan2. Gemcitabine & Topotecan 	Did not meet primary endpoint of OS
Meier et al. 2009 (AGO-OVAR 2.3) 	1998-2002 	Phase 3 (E-switch-ic) 	Treosulfan 	Longer OS (primary endpoint)Median OS: 55 vs 41 weeks(HR 0.67, 95% CI 0.52-0.87)
Sehouli et al. 2010 (TOWERov) 	2005-2008 	Randomized Phase 2 (C)	Topotecan; weekly 	Did not meet primary endpoint of CBR
Pujade-Lauraine et al. 2014 (AURELIA)	2009-2011 	Phase 3 (C) 	1a. Paclitaxel & Bevacizumab1b. PLD & Bevacizumab1c. Topotecan & Bevacizumab 	Shorter PFSMedian PFS: 3.4 vs 6.7 mo(HR 2.08, 95% CI 1.67-2.63)
Kurzeder et al. 2016 (PENELOPE) 	2013-10-02 to 2014-09-18 	Phase 3 (C) 	1a. Gemcitabine & Pertuzumab1b. Paclitaxel & Pertuzumab1c. Topotecan & Pertuzumab	Did not meet primary endpoint of PFSMedian PFS: 2.6 vs 4.3 mo(sHR 1.35, 95% CI 0.90-2.00)
Lee et al. 2024 (NRG-GY005) 	2016-02-05 to 2020-10-02 	Phase 2/3 (C) 	1. Olaparib2. Cediranib & Olaparib 	Did not meet co-primary endpoints of PFS/OS
Moore et al. 2021 (FORWARD I) 	2017-01-24 to 2018-04-23 	Phase 3 (C) 	Mirvetuximab soravtansine 	Did not meet primary endpoint of PFSMedian PFS: 4.4 vs 4.1 mo(HR 1.02, 95% CI 0.76-1.37)
Moore et al. 2023 (MIRASOL) 	2020-02-03 to not reported	Phase 3 (C) 	Mirvetuximab soravtansine 	Shorter OSMedian OS: 12.75 vs 16.46 mo(HR 1.49, 95% CI 1.12-2.00)Shorter PFSRMPFS12: 4.72 vs 6.13 mo
Awaiting publication (NItCHE) 	2020-ongoing 	Phase 3 (C) 	Niraparib & Dostarlimab 	TBD if different primary endpoint of OS
Note: this was the dosing used in third-line therapy in AGO-OVAR 2.3. TOWER should not be confused with the trial by the same name in B-ALL.
====Biomarker eligibility criteria====
*FORWARD I & MIRASOL: High folate receptor-alpha expression
====Chemotherapy====
*Topotecan (Hycamtin) 1.25 mg/m2 IV over 30 minutes once per day on days 1 to 5
21-day cycles for varying durations: 18 cycles (TOWERov); indefinitely (all others)
===Regimen variant #3, 7.5 mg/m2, split dosing, q3wk===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Bookman et al. 1996 	Not reported 	Phase 2 (RT) 	 	
ten Bokkel Huinink et al. 1997 	Not reported 	Randomized (E-RT-switch-ic)	Paclitaxel 	Might have longer TTP1 (co-primary endpoint)Median TTP: 18.9 vs 14.7 weeks(HR not reported, p=0.08)
Gordon et al. 2001 (Doxil Study 30-49)	1997-1999 	Phase 3 (C) 	PLD 	Seems to have shorter PFS (co-primary endpoint)Median PFS: 23.3 vs 28.9 weeks(HR not reported, p=0.037)
Meier et al. 2009 (AGO-OVAR 2.3) 	1998-2002 	Phase 3 (E-switch-ic) 	Treosulfan 	Shorter OS (primary endpoint)Median OS: 41 vs 55 weeks(HR 1.49, 95% CI 1.15-1.92)
Gaillard et al. 2021 (CORAIL) 	2015-06-26 to 2018-10-12	Phase 3 (C) 	Lurbinectedin	Did not meet primary endpoint of PFSMedian PFS: 3.6 vs 3.5 mo(HR 0.95)
1Reported efficacy for ten Bokkel Huinink et al. 1997 is based on the 2004 update.
Note: this was the dosing used in second-line therapy in AGO-OVAR 2.3.
====Chemotherapy====
*Topotecan (Hycamtin) 1.5 mg/m2 IV over 30 minutes once per day on days 1 to 5
21-day cycles
===References===
# Bookman MA, Malmström H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998 Oct;16(10):3345-52. link to original article EuroPMC
# ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmström H, Coleman R, Fields SC, Heron JF. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997 Jun;15(6):2183-93. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
## Update: ten Bokkel Huinink W, Lane SR, Ross GA; International Topotecan Study Group. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol. 2004 Jan;15(1):100-3. link to original article EuroPMC
# Doxil Study 30-49: Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001 Jul 15;19(14):3312-22. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
## Update: Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004 Oct;95(1):1-8. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P, Stauch M, Paulenz A, Camara O, Keil E, Lichtenegger W; North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2008 Jul 1;26(19):3176-82. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# AGO-OVAR 2.3: Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück HJ, Kimmig R, Pfisterer J. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy: a prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2009 Aug;114(2):199-205. Epub 2009 May 14. link to original article dosing details in supplement have been reviewed by our editors EuroPMC
# TOWER: Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, Mahner S, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl HG, Schroeder W, Lichtenegger W, Oskay-Oezcelik G; North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2011 Jan 10;29(2):242-8. Epub 2010 Nov 29. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00170677
# AURELIA: Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. Epub 2014 Mar 17. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00976911
## PRO analysis: Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. Epub 2014 Mar 31. link to original article link to PMC article EuroPMC
## Subgroup analysis: Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. link to original article EuroPMC
# PENELOPE: Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Ottevanger P, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, Del Campo JM, Mahner S, Bastière-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A, Gonzalez-Martin A. Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-expressing platinum-resistant ovarian cancer (PENELOPE). J Clin Oncol. 2016 Jul 20;34(21):2516-25. Epub 2016 Jun 6. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01684878
## Update: Lorusso D, Hilpert F, González Martin A, Rau J, Ottevanger P, Greimel E, Lück HJ, Selle F, Colombo N, Kroep JR, Mirza MR, Berger R, Pardo B, Grischke EM, Berton-Rigaud D, Martinez-Garcia J, Vergote I, Redondo A, Cardona A, Bastière-Truchot L, du Bois A, Kurzeder C; PENELOPE trial investigators. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2019 Sep;29(7):1141-1147. Epub 2019 Aug 15. link to original article EuroPMC
# FORWARD I: Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Konecny GE, Banerjee S, Murphy CG, Tanyi JL, Hirte H, Konner JA, Lim PC, Prasad-Hayes M, Monk BJ, Pautier P, Wang J, Berkenblit A, Vergote I, Birrer MJ. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021 Jun;32(6):757-765. Epub 2021 Mar 2. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT02631876
#CORAIL: Gaillard S, Oaknin A, Ray-Coquard I, Vergote I, Scambia G, Colombo N, Fernandez C, Alfaro V, Kahatt C, Nieto A, Zeaiter A, Aracil M, Vidal L, Pardo-Burdalo B, Papai Z, Kristeleit R, O'Malley DM, Benjamin I, Pautier P, Lorusso D. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). Gynecol Oncol. 2021 Nov;163(2):237-245. Epub 2021 Sep 11. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT02421588
#MIRASOL: Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 Dec 7;389(23):2162-2174. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT04209855
#NRG-GY005: Lee JM, Brady MF, Miller A, Moore RG, MacKay H, McNally L, Lea J, Street D, Lheureux S, McDonald ME, Duska LR, Cantuaria G, Kavecansky J, Leath CA 3rd, Powell M, Cadungog MG, Rose PG, Kim YM, Huang HQ, Provencher M, Wenzel LB, Bookman MA, Kohn EC, Secord AA. Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005. J Clin Oncol. 2024 Dec 20;42(36):4305-4316. Epub 2024 Oct 3. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT02502266
# DOXILOVC3001: NCT01840943
# NItCHE: NCT04679064
==Topotecan & Bevacizumab==
===Regimen variant #1, topotecan 3 weeks out of 4===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Pujade-Lauraine et al. 2014 (AURELIA)	2009-2011 	Phase 3 (E-RT-esc)	1a. Paclitaxel1b. PLD1c. Topotecan	Longer PFS (primary endpoint)Median PFS: 6.7 vs 3.4 mo(HR 0.48, 95% CI 0.38-0.60)
====Chemotherapy====
*Topotecan (Hycamtin) 4 mg/m2 IV once per day on days 1, 8, 15
====Targeted therapy====
*Bevacizumab (Avastin) 10 mg/kg IV once per day on days 1 & 15
28-day cycles
===Regimen variant #2, topotecan 6.25 mg/m2, split dosing, q3wk===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Pujade-Lauraine et al. 2014 (AURELIA)	2009-2011 	Phase 3 (E-RT-esc)	1a. Paclitaxel1b. PLD1c. Topotecan	Longer PFS (primary endpoint)Median PFS: 6.7 vs 3.4 mo(HR 0.48, 95% CI 0.38-0.60)
====Chemotherapy====
*Topotecan (Hycamtin) 1.25 mg/m2 IV once per day on days 1 to 5
====Targeted therapy====
*Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycles
===References===
# AURELIA: Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. Epub 2014 Mar 17. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00976911
## PRO analysis: Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. Epub 2014 Mar 31. link to original article link to PMC article EuroPMC
## Subgroup analysis: Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. Epub 2016 Nov 18. link to original article EuroPMC
# NItCHE: NCT04679064
==Trabectedin monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence
Krasner et al. 2007	2002-2004 	Phase 2
====Chemotherapy====
*Trabectedin (Yondelis) 0.58 mg/m2 IV over 3 hours once per day on days 1, 8, 15
====Supportive therapy====
*Dexamethasone (Decadron) 10 mg IV once per day on days 1, 8, 15, given 30 minutes prior to chemotherapy
28-day cycles
===References===
# Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer. 2007 Dec 17;97(12):1618-24. Epub 2007 Nov 13. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC
==Treosulfan monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Meier et al. 2009 (AGO-OVAR 2.3)	1998-2002 	Phase 3 (E-switch-ic)	Topotecan 	Shorter OS (primary endpoint)Median OS: 41 vs 55 weeks(HR 1.49, 95% CI 1.15-1.92)
Sehouli et al. 2016 	2002-2014 	Phase 3b (C) 	Treosulfan; PO	Might have longer OS
====Chemotherapy====
*Treosulfan (Ovastat) by the following renal function-based criteria:
**CrCl more than 40 mL/min/1.73 m2: 7000 mg/m2 IV once on day 1
**CrCl 20 to 40 mL/min/1.73 m2: 6000 mg/m2 IV once on day 1
**CrCl less than 20 mL/min/1.73 m2: 5000 mg/m2 IV once on day 1
28-day cycles
===References===
# AGO-OVAR 2.3: Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück HJ, Kimmig R, Pfisterer J. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy: a prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2009 Aug;114(2):199-205. Epub 2009 May 14. link to original article dosing details in supplement have been reviewed by our editors EuroPMC
# Sehouli J, Tomè O, Dimitrova D, Camara O, Runnebaum IB, Tessen HW, Rautenberg B, Chekerov R, Muallem MZ, Lux MP, Trarbach T, Gitsch G. A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO). J Cancer Res Clin Oncol. 2017 Mar;143(3):541-550. Epub 2016 Nov 28. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC
==Vinorelbine monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence
Rothenberg et al. 2004	1995-03 to 1997-07 	Phase 2
====Chemotherapy====
*Vinorelbine (Navelbine) 30 mg/m2 IV once per day on days 1 & 8
21-day cycles
===References===
# Rothenberg ML, Liu PY, Wilczynski S, Nahhas WA, Winakur GL, Jiang CS, Moinpour CM, Lyons B, Weiss GR, Essell JH, Smith HO, Markman M, Alberts DS; SWOG. Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. Gynecol Oncol. 2004 Dec;95(3):506-12. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
Category:Ovarian cancer regimens
Category:Disease-specific pages
Category:Gynecologic cancers